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the inflammatory process in Parkinson’s disease. Based on this project, I was invited 
by Professor Torben Moos to become a spare-time researcher in the Laboratory of 
Neurobiology working on immune cell entry and iron handling in Parkinson’s disease.  
Besides this spare-time research, me and my study group’s interests moved in the 
direction of brain cancer and microRNA dysregulation. This interest was originally 
sparked by a student project in early 2011, where the conditioned medium of adipose-
derived stem cells was found to inhibit the growth on glioblastoma multiforme cells 
in culture – a result and presentation of it, which was awarded the Best Poster 
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cited, systematic review on microRNA dysregulation in glioblastoma multiforme. 
For my Master’s degree, written under the supervision of Associate Professor Meg 
Duroux and then PhD student Michael Henriksen in the Laboratory of Cancer 
Biology, I chose to work on yet another derivation from the project on conditioned 
medium, namely the content of exosomes and other extracellular vesicles, and how 
these endogenous nanoparticles could be used as drug delivery vehicles to transport 
microRNA-regulating medicines to brain tumors. While this work did not end in a 
new curative treatment for glioblastoma multiforme, it resulted in a huge amount of 
knowledge regarding nanoparticle characterization and drug delivery in general. In 
addition, it led to contributions in four published papers (two as first author) regarding 
either the dysregulation of microRNAs in glioblastoma multiforme patient, or issue 
pertaining to the use of exosomes as drug delivery vehicles.  
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ENGLISH SUMMARY 
Efficient drug delivery to the brain remains the largest obstacle for treatment of 
diseases related to the central nervous system. This obstacle is imposed by the 
presence of the blood-brain barrier (BBB), which constitutes the endothelial lining of 
the brain capillaries. The brain capillary endothelial cells of the BBB are characterized 
by very tight interconnections and low passive permeability, and therefore, they 
effectively exclude most molecules carried in the systemic circulation from entering 
the sensitive brain parenchyma. This also means that transport of medicines into the 
brain is severely impaired. One strategy to overcome the issue of the BBB has been 
to target the medicines as drug constructs or nanomedicines to different nutrient 
receptor proteins expressed on the surface of the BBB. This would in theory drag the 
medicines into the brain parenchyma as a blind passenger together with the nutrient 
molecule. One popular receptor system utilized for brain drug delivery is the 
transferrin receptor, which is normally responsible for transporting iron atoms into the 
brain. However, despite vast amounts of preclinical progress in the past three decades 
on the use of transferrin receptors for brain drug delivery, there is still a lack of clinical 
translation. 
In this dissertation, transferrin receptor-mediated brain drug delivery via 
nanomedicines was studied to obtain knowledge about specific design aspects that 
could improve the current standard of transport across the BBB. Specifically, we 
studied the impact of ligand affinity, avidity, and valency on the subsequent uptake of 
gold nanoparticles and liposomes. Furthermore, we studied the fate of nanoparticles 
administrated directly into the brain compartment via intracerebroventricular 
injection. We find that between the different aspects studied, the impact imposed by 
decreasing the valency of a TfR-targeting antibody was superior with respect to 
increasing the brain parenchymal exposure of intravenously administrated 
nanoparticles. This amounted to a more than five-fold increase compared to current 
standards. We also find that a net negative surface charge is favorable for deep 
penetration of nanoparticles into the brain cortex after intracerebroventricular 
administration. In conclusion, the results presented in this dissertation provide 
important information about how aspects known to impact antibody-based medicines 
for the brain also may impact the transport of nanomedicines into the brain.  
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DANSK RESUME 
Effektiv lægemiddeltilførsel til hjernen er fortsat den største hindring for behandling 
af sygdomme i centralnervesystemet. Denne hindring opstår ved tilstedeværelsen af 
blod-hjerne-barrieren, som udgøres af endotelcellelaget i hjernens kapillærer. 
Endotelcellerne i hjernens kapillærer er karakteriseret ved meget tætte intercellulære 
forankringer og lav passiv permeabilitet, og derved udelukker de effektivt de fleste 
molekyler, der findes i den blodsystemet fra at komme ind i det følsomme hjernevæv. 
Dette betyder også, at transport af lægemidler til hjernen i de fleste tilfælde er 
forhindret. En strategi til at passere blod-hjerne-barrieren har været at målrette 
lægemidlet som lægemiddelkonstrukter eller nanomedicin til forskellige receptorer 
udtrykt på overfladen af blod-hjerne-barrieren, der normalt er ansvarlig for transport 
af næringsstoffer ind i hjernen. Dette vil i teorien trække lægemidlet ind i hjernevævet 
som en blind passager sammen med næringsstofmolekylet. Et populært 
receptorsystem til dette formål er transferrinreceptoren, som normalt er ansvarlig for 
transport af jernatomer ind i hjernen. Men på trods af store mængder prækliniske 
fremskridt i seneste sidste tre årtier vedrørende anvendelsen af transferrinreceptorer 
til medicinlevering til hjernen er der dog stadig mangel på klinisk fremskridt.  
I denne afhandling undersøges transferrinreceptormedieret, nanomedicinbaseret 
lægemiddellevering til hjernen for at opnå viden om specifikke designaspekter, der 
kan forbedre det nuværende niveau af transport over blod-hjerne-barrieren. Specifikt 
studerede vi virkningen af ligandaffinitet, aviditet og valens på den efterfølgende 
optagelse af guldnanopartikler og liposomer. Desuden studerede vi nanopartiklers 
mobilitet efter direkte administration ind i centralnervesystemet via 
intracerebroventrikulær injektion. Vi finder, at mellem de forskellige designaspekter, 
der blev studeret, var virkningen ved at nedsætte valensen af et 
transferrinreceptorantistof overlegen med hensyn til forøgelse af hjernens 
eksponering af intravenøst administrerede nanopartikler. Dette resulterede i en mere 
end femfolds stigning i forhold til andre undersøgte formuleringer. Vi finder også, at 
en negativ overfladeladning er gunstig for penetration af nanopartikler ind i 
hjernebarken efter intracerebroventrikulær administration. Afslutningsvis giver 
resultaterne i denne afhandling vigtige oplysninger om, hvordan designaspekter, der 
på nuværende tidspunkt vides at påvirke antistofbaserede lægemidler til hjernen, også 
kan påvirke transporten af nanomedicin ind i hjernen. 
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PREFACE 
The work presented in this dissertation was carried out between 2014 and 2017 as a 
part of a PhD programme under the Faculty of Medicine at Aalborg University. The 
dissertation contains different manuscripts focusing on the use of the transferrin 
receptor as a target for brain drug delivery. Different aspects pertaining to the use of 
the transferrin receptor was studied, including the possible impact of ligand valency 
and affinity on the transport of nanoparticles into the brain. Furthermore, differences 
with respect to the transport of nanoparticles versus encapsulated cargo into the brain 
was studied. 
The dissertation is structured such that the classical Introduction section is omitted in 
favor of the inclusion of two published review manuscripts (Manuscript I – II, one 
journal paper and one book chapter). The two following manuscripts will thus serve 
as Introduction (Chapter 1) for the experimental chapters presented later: 
- Manuscript I: Johnsen KB, Moos T. Revisiting nanoparticle technology for 
blood-brain barrier transport: Unfolding at the endothelial gate improves the 
fate of transferrin receptor-targeted liposomes. J Control Release. 2016 Jan 
28;222:32–46. 
 
- Manuscript II: Johnsen KB, Burkhart A, Andresen TL, Moos T, Thomsen 
LB. The use of the transferrin receptor as a target for brain drug delivery 
using nanomedicines. In: Gaillard PJ, Morales J, editors. Nanomedicines 
for Brain Drug Delivery – Springer Nature Neuromethods Series. Springer 
Nature; 2017. In press.  
In addition to these introductory manuscripts, another chapter has been added to the 
dissertation, wherein the principles behind the main methodology used in the 
experimental manuscripts are described, as well as our considerations for the use of 
these specific methods (Chapter 2). 
The experimental part of the dissertation is divided into four manuscripts regarding 
the use of the transferrin receptor as a target for brain drug delivery (Manuscript III – 
V), and the distribution of nanoparticles in the brain compartment after direct 
administration (Manuscript VI). These manuscripts (published or in preparation) are 
included in this dissertation as Chapter 4: 
- Manuscript III: Johnsen KB, Burkhart A, Melander F, Kempen PJ, Vejlebo 
JB, Siupka P, et al. Targeting transferrin receptors at the blood-brain barrier 
improves the uptake of immunoliposomes and subsequent cargo transport 
into the brain parenchyma. Sci Rep. 2017 Sep 4;7(1):437. 
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- Manuscript IV: Johnsen KB, Bak M, Kempen PJ, Melander F, Burkhart A, 
Thomsen MS, Nielsen MS, Andresen TL, Moos T. Antibody affinity and 
valency impact the brain uptake of transferrin receptor-targeted gold 
nanoparticles. Submitted to Science Advances. 
 
- Manuscript V: Johnsen KB, Bak M, Kempen PJ, Melander F, Thomsen MS, 
Burkhart A, Andresen TL, Moos T. Modulating the ligand density changes 
the brain uptake of transferrin receptor-targeted gold nanoparticles and 
liposomal cargo. In preparation. 
 
- Manuscript VI: Johnsen KB, Vejlebo JB, Andresen TL, Moos T. The surface 
charge depicts the brain distribution of liposomes after intracerebro-
ventricular administration – a morphological study. In preparation. 
The dissertation ends with a joint discussion on the features of brain drug delivery 
(and transferrin receptor targeting) covered in the six manuscripts, but with a focus on 
the on the broad aspects that were observed across multiple manuscripts (Chapter 5). 
This discussion also describes the perspectives of the studies that will be relevant to 
investigate in future work.  
I hope that the work will be of great interest for the reader, and that the reader will 
enjoy the contents of the dissertation. 
 
Kasper Bendix Johnsen, December 2017  
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1.1. MANUSCRIPT I 
Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at 
the gate improves the fate of transferrin receptor-targeted liposomes 
Kasper Bendix Johnsen & Torben Moos* 
Laboratory for Neurobiology, Biomedicine, Institute of Health Science and 
Technology, Aalborg University, Aalborg, Denmark. 
Manuscript published in Journal of Controlled Release 
Abstract 
An unmet need exists for therapeutic compounds to traverse the brain capillary 
endothelial cells that denote the blood-brain barrier (BBB) to deliver effective 
treatment to the diseased brain. The use of nanoparticle technology for targeted 
delivery to the brain implies that targeted liposomes encapsulating a drug of interest 
will undergo receptor-mediated uptake and transport through the BBB with a 
subsequent unfolding of the liposomal content inside the brain, hence revealing drug 
release to adjacent drug-demanding neurons. As transferrin receptors (TfRs) are 
present on brain capillary endothelial, but not on endothelial cells elsewhere in the 
body, the use of TfR-targeted liposomes - colloidal particulates with a phospholipid 
bilayer membrane - remains the most relevant strategy to obtain efficient drug 
delivery to the brain. However, many studies have failed to provide sufficient 
quantitative data to proof passage of the BBB and significant appearance of drugs 
inside the brain parenchyma. Here, we critically evaluate the current evidence on the 
use of TfR-targeted liposomes for brain drug delivery based on a thorough 
investigation of all available studies within this research field. We focus on issues 
with respect to experimental design and data analysis that may provide an explanation 
to conflicting reports, and we discuss possible explanations for the current lack of 
sufficient transcytosis across the BBB for implementation in the design of TfR-
targeted liposomes. We finally provide a list of suggestions for strategies to obtain 
substantial uptake and transport of drug carriers at the BBB with a concomitant 
transport of therapeutics into the brain. 
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1.2. MANUSCRIPT II 
The use of the transferrin receptor as a target for brain drug delivery using 
nanomedicines 
Kasper Bendix Johnsen1,2*, Annette Burkhart1, Thomas Lars Andresen2, Torben 
Moos1 & Louiza Bohn Thomsen1 
1Laboratory for Neurobiology, Biomedicine, Institute of Health Science and 
Technology, Aalborg University, Aalborg, Denmark. 2Center for Nanomedicine and 
Theranostics, Department of Micro- and Nanotechnology, Technical University of 
Denmark, Denmark. 
Manuscript published as a book chapter in Nanomedicines for Brain Drug Delivery – 
Springer Nature Neuromethods Series 
Abstract 
Millions worldwide suffer from neurological disorders, and even more will be 
affected by e.g. Alzheimer’s disease and cerebrovascular diseases in the coming 
decades. The possibilities for treatment of neurological diseases are hampered by that 
drug delivery to the brain is severely impaired by the blood-brain barrier (BBB), 
which function is to regulate the fluxes of molecules between the circulation and the 
brain. Development of successful strategies to bypass the integrity of the BBB is thus 
pivotal to obtain tools that will allow for treatment of diseases of the central nervous 
system. To develop such bypassing strategies, it is also of great importance to 
understand the morphological and physiological features that characterize the BBB. 
In this chapter, the structure and function of the BBB and the current knowledge on 
the role of the transferrin receptor in brain iron uptake is reviewed. This is followed 
by a full coverage of the functions of the transferrin receptor and its ligands together 
with a thorough summary of studies investigating the delivery of transferrin receptor-
targeted nanomedicines. The challenges of the transferrin receptor-targeting strategy 
are discussed with emphasis on possibilities to improve brain delivery while avoiding 
typical experimental caveats. 
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CHAPTER 2. METHODOLOGICAL CONSIDERATIONS 
The purpose of this chapter is to give a broad overview of the methodology applied in 
the subsequent studies of TfR-mediated brain drug delivery. The individual 
subsections will include the main principles of each technique and the historical 
background regarding their development. Furthermore, the considerations we had for 
including the specific methods in our studies are also presented. All projects presented 
later in this dissertation was based on collaborations between two groups, who are 
experts in neurobiology and nanomedicine, respectively. Therefore, a significant 
amount of knowledge transfer between the groups is needed to fully comprehend the 
data output and the interpretations based on it. This next chapter seeks to bridge the 
gap.  
2.1. IN VITRO MODELLING OF THE BLOOD-BRAIN BARRIER 
Given the important role that the BBB plays in the regulation of the brain 
microenvironment by governing the entrance of most types of molecules, studies of 
the BBB to understand this regulation and exploit it for drug delivery is crucial (1). 
However, these studies are not trivial to perform in vivo, because the BBB exists as a 
complex network in the brain vasculature, which is mostly inaccessible for studies of 
intracellular mechanisms or transport across the BBB (2). It may also be difficult to 
decipher the roles of specific cellular or non-cellular components in regulating these 
mechanisms, because the proximity of the different components limits the resolution 
with which we can identify and describe these roles. Knock-out animal models exist 
where a specific cell type is lost, but these models only illustrate an extreme situation 
and do not necessarily mimic a situation that resembles any disease (3, 4). 
Furthermore, the bioethical aspect of the use of animals for experimental studies 
requires consideration about reducing the number of animals or replacing the animals 
with other models giving a similar answer to the scientific question (5-7). 
Many researchers have tried to overcome these issues by modelling the BBB in vitro 
using advanced culture systems. These efforts were started already in the 1970s, 
where BCECs were cultured from microcapillaries isolated from brain homogenates 
via sucrose centrifugation (an early version of the brain capillary depletion technique, 
see below)(8, 9). These isolated BCECs were used as simple models of the BBB to 
study the regulation of transporters and integrity of TJ protein assemblies (Figure 
2.1.1)(10-14). However, these models were limited by the fact that they did not 
produce a tight monolayer of BCECs, which is a main requirement for in vitro BBB 
models (1). Some also reported that the activity of the endothelial-specific enzyme g-
glutamyl transferase was lost in culture (15), hereby illustrating that in culture the 
BCECs were not fully differentiated and capable of producing a functional BBB.  
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Later, a series of studies illustrated that culturing the BCECs in the presence of 
astrocytes or astrocyte-like cells led to re-induction of BCEC characteristics, e.g. g-
glutamyl transferase activity and TJ protein expression (16, 17). This suggested that 
the presence of astrocytes was important for maintaining the integrity of the BCEC 
monolayer, corresponding well with the almost full coverage of the BCECs by 
astrocytic endfeet in vivo (18-24). With the introduction of the now widely popular 
Transwell co-culture system, Dehouck et al. (1990) cultured bovine BCECs and rat 
astrocytes in the so-called contact co-culture format (Figure 2.1.1) and showed that 
this raised the transendothelial electrical resistance (TEER) of the BCEC monolayer 
remarkably together with decreasing the passive permeability to small molecules (17). 
These factors are important to prove since they correlate with the BCECs obtaining 
their proper polarization, and thus, it is now widely accepted that co-culture of BCECs 
with astrocytes is a crucial requirement for obtaining a relevant in vitro BBB model 
system to perform studies in (1). The induction is even possible when using the so-
called non-contact co-culture models, where the astrocytes are seeded in the bottom 
chamber of the Transwell co-culture system (Figure 2.1.1), illustrating how much of 
the inductor properties of the astrocytes that are mediated by their release of soluble 
factors to the microenvironment (1). Furthermore, having access to these 
commercially available Transwell co-culture systems also sparked the idea of 
including the last cellular component of the NVU, namely the pericytes (25-30). In 
vivo, the pericytes (like astrocytes) are responsible for maintaining the integrity of the 
BCEC monolayer, but there are also indications that they are important for regulating 
the capillary blood flow (3, 31-34). In vitro, some have found that including the 
pericytes into the co-culture systems (to obtain a triple co-culture, Figure 2.1.1) 
improved the TEER values of the resulting BBB model (25), whereas others failed to 
make this observation (35). Pericytes are also known to reduce the vesicular transport 
in vivo, but this role has not been described yet for in vitro models, although it would 
likely underscore the system’s validity, if such intracellular mechanisms could be 
successfully modelled (3, 4, 36). 
 
Figure 2.1.1. Schematic representation of in vitro models of the blood-brain barrier. BCECs can be isolated 
and cultured in different setups to mimic the normal blood-brain barrier, and these different setups result in 
very different outcomes with respect to proper differentiation and polarization. (A) The simplest model, 
called the mono-culture model, consists only of BCECs and is characterized by low values of TEER and 
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poor differentiation and polarization. (B + C) Co-culture models with astrocytes can be set up both as non-
contact or contact co-cultures. These models are characterized by a marked increase in BBB integrity and 
mimicry. (D) Pericytes can also be introduced to create the so-called triple co-culture models. These models 
are not characterized by increased TEER values, but may have an impact on decreasing the vesicular 
transport as is evident in vivo. 
To ease the use of in vitro BBB models, several groups have developed immortalized 
BCEC lines derived from a variety of different species, and these cell lines have 
gained huge popularity. For example, transfection of mouse BCECs with polyoma 
middle T antigen resulted in the generation of the bEnd.3 cell line, which have been a 
work horse in many laboratories to this day (37). Similar approaches have been used 
to generate the RBE4 cell line from rat cells (38), or hCMEC/D3 and HBMEC lines 
from human cells (39, 40). These cell lines are easy to culture and they express several 
important receptors and transporters, which make them useful for many purposes, 
especially regarding drug delivery screening processes (41). However, it is also 
evident that none of these cell lines can produce a tight monolayer of BCECs, as 
shown by the low TEER values and high passive permeability of the resulting in vitro 
BBB models (1). This can possibly be overcome for the study of larger drug molecules 
or carriers (e.g. antibodies and nanoparticles), if a pulse-chase strategy is employed 
(42). In this system, primary binding and uptake into the BCEC is allowed in one well, 
followed by extensive washing of the BCECs and transfer of the Transwell into 
another well (bottom compartment) from which the transported drug molecule is 
sampled (42). Still, regardless of their high-throughput qualities, the immortalized cell 
lines will never produce models as good as those derived from primary BCECs, and 
thus, to study BBB biology, the primary in vitro BBB models are state-of-the-art in 
comparison (43-45).  
Primary in vitro models of the BBB have until now been produced from mouse (35), 
rat (46-49), bovine (2, 50), porcine (51), and human BCECs (52, 53), and their utility 
as models of the true BBB have to some extent been proven in numerous studies. 
However, there are still many issues to consider, when using the in vitro BBB models 
to base conclusions on, especially because only very few studies have provided 
correlative evidence based on parallel in vitro and in vivo studies (49). One study 
compared the transport profile of different antibody constructs targeting undisclosed 
BBB receptors and found a good correlation between the in vitro and in vivo data, 
which indicates that some transport is happening similarly in the two systems (45). 
Others have failed to reproduce the function of the TfR for transporting iron across 
the BBB, a function which has been known for decades to exist in vivo (54). This 
finding was interpreted be due to interaction between iron and the permeable support 
of the Transwell, which illustrates how transport data may be underestimated because 
of this interaction (54, 55). It was also shown that despite of having a high integrity 
in vitro BBB model, the barriers contain a high number of holes in the endothelial 
monolayer that can be impossible to detect with the resolution of normal fluorescence 
microscopes (55, 56). These holes represent a sink for nanoparticles administrated to 
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these barriers, which would result in an overestimation of the transport efficiency (55). 
Whether these holes are a universal phenomenon in all in vitro BBB models is yet to 
be shown. 
The use of in vitro BBB models throughout the projects described in this dissertation 
has served both as tools for optimization (such as flow cytometry-based studies in 
immortalized cell lines) and as parts of parallel assessments together with in vivo 
experiments of how the different types of nanoparticles were taken up into BCECs 
and transported across the BBB. A choice was made to avoid the use of triple cultures 
with pericytes, since adding this cell type to the system would yield another source of 
error in addition to factors such as unspecific interaction between the transcytosed 
nanoparticles and the polycarbonate membrane of the Transwell inserts (55). 
However, this still produced in vitro BBB models with high integrity, as determined 
by high values of TEER, and the expression of relevant TJ proteins. Furthermore, the 
TEER values were measured immediately before and after a nanoparticle transport 
experiment to ensure that the integrity of the in vitro BBB model was maintained 
despite the presence of nanoparticles in the growth medium. Depending on the type 
of nanoparticle that was administrated to the models, the correlation between the in 
vitro and in vivo systems varied from negative to positive, but especially for 
experiments on AuNPs there was a good correlation. Still, in all cases, the absolute 
amounts of compound transported across the in vitro BBB models were very low. This 
may both be a testament to the overall low transport capacity of the nanoparticle 
systems, but also to the fact that while it was possible to measure transport to the 
‘brain’ compartment of the Transwell setup, some of the transcytosed nanoparticles 
or cargo will inevitably still be interacting with the polycarbonate membrane (55). 
2.2. BRAIN CAPILLARY DEPLETION 
When studying the relevance of a new nanomedicine strategy for brain drug delivery, 
one must know about its uptake capacity into the brain parenchyma. The most widely 
used methods for this purpose are measurements of the compound of interest 
(nanoparticle, elements of the nanoparticle, or therapeutic cargo) in homogenates of 
the brain (57, 58), or labelling of the nanoparticle and therapeutic cargo to facilitate 
imaging of the brain accumulation using e.g. positron emission tomography (PET)(59, 
60). Both methods are suitable for giving an answer to the basic question about 
whether the newly developed nanomedicine will preferentially accumulate in the 
region of the brain. Thus, many studies argue for the relevance of their nanomedicine 
strategies by presenting such evidence to show that brain accumulation will occur 
after intravenous injection, and often interpret such findings as indicative of transport 
into the brain parenchyma (58, 61). However, these interpretations will often be 
flawed by the fact that the impact of the BBB on the transport of the nanoparticle into 
the brain is seldom accounted for, especially if these observations are used as a 
standalone argument. 
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The experiments performed in vivo for this project are focused on obtaining 
knowledge about the transport capacity of the different strategies studied, and less 
about the possible therapeutic impact this would have subsequently (49). Therefore, 
there was a need for a methodology that would allow for answering both the broad 
question of whether the nanoparticles reached the brain region, together with more 
advanced questions on the whereabouts of the nanoparticles after this brain regional 
accumulation, i.e. whether the nanoparticles had the ability of being transported across 
the BBB into the brain parenchyma, or whether the nanoparticles simply remained 
confined inside the BCECs (49, 62). To answer these questions, the so-called brain 
capillary depletion method was employed, because this method separates the vascular 
compartment from the rest of the brain tissue (63). The method was originally 
described by Triguero et al. (1990), where forebrain tissue was homogenized in a 
buffer solution and mixed with high concentrations of dextran (Figure 2.2.1)(64). The 
homogenization is thought to release the microvasculature from the other cell types 
of the brain, which will associate with the dextran beads in the solution. The dextran 
bead-associated microvasculature can then be pelleted by centrifugation at high speed 
(Figure 2.2.1)(64). After the centrifugation, the homogenized brain samples are 
separated into a capillary-containing pellet and a supernatant containing the brain 
parenchymal fraction. The purity of these fractions can be analyzed, e.g. by measuring 
the activity of endothelial cell-associated enzymes (alkaline phosphatase and g-
glutamyl transferase)(64-66), or performing microscopic assessment of the different 
fractions to look for the morphology of the cells contained in the samples (64, 65). 
For the latter, immunocytochemistry can be included to illustrate high abundance of 
endothelial markers such as CD31 or claudin 5. Generally, studies using this method 
find a high purity of the two fractions after separation, which highlights the relevance 
of including this method in studies of drug transport across the BBB (63, 64, 67, 68). 
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Figure 2.2.1. Schematic representation of the brain capillary depletion technique. Samples of the brains are 
resected and homogenized in a buffer solution, mixed with a high concentration of dextran, and centrifuged 
at high speed. The combined effect of this dextran addition and subsequent centrifugation is the separation 
of the brain capillaries (red pellet) from the brain parenchyma, which is found both as a supernatant (blue 
with cloud of tissue) and a so-called lipid cake (beige plug on top of the supernatant). All fractions are 
sampled for downstream analysis of transport across the blood-brain barrier in vivo. 
Since the original publication of the protocol, the method has been used in a relatively 
steady amount of studies each year (approximately four published articles per year). 
Some find their compounds to accumulate mostly in the brain capillaries with low 
transport across the BBB (65, 69), whereas others find their compounds to be 
upconcentrated in the parenchymal fraction with low levels of accumulation inside 
the BCECs (70). In relation to studies regarding endogenous compounds (i.e. with no 
therapeutic purpose), the validity of the method was illustrated by showing receptor-
mediated endocytosis of acetylated low-density lipoprotein (LDL) without subsequent 
exocytosis to the brain parenchymal compartment (64), and vascular sequestration of 
adenosine after carrier-mediated uptake into the BCECs (67). However, the protocol 
has not gained wide popularity within studies of brain drug delivery, mostly because 
researchers employ a functional (therapeutic) outcome measure in their studies, which 
indirectly proves the transport capacity. Such indirect proof may be relevant in many 
occasions, but given the low clinical progress of nanomedicines for brain drug 
delivery, there may be valuable knowledge to gain about why so little transport is 
happening, if more detailed studies on the nanomedicine strategy itself are performed.  
Criticism has been made regarding brain capillary depletion due to possible imperfect 
separation of all capillaries from the parenchymal fraction, and the risk of spillover 
between fractions after the centrifugation procedure (63, 65, 71). This was evidenced 
by dissociation of compounds binding with low affinity to the plasma membrane of 
the BCECs, e.g. a µ-opioid peptide-dermorphin analogue (68). Purity of the fractions 
may be increased by subjecting the isolated brain to the currently used protocols for 
isolation BCECs for advanced in vitro culture systems (35, 46, 51), but this also 
undermines the quantitative aspect that is an important positive feature of the brain 
capillary depletion technique. Thus, it is evident that although being much more 
advanced than studies made on whole brain homogenates, the outcome of the brain 
capillary depletion technique may be used only as an approximation of the transport 
capacity, and should preferably be combined with other methods (e.g. morphology-
based) that can underscore the quantitative findings. Another relevant combinatorial 
technique could be the use of microdialysis directly from the brain extracellular space 
(72-74). 
Brain capillary depletion was employed in all quantitative in vivo experiments 
presented in this dissertation. One hemisphere from each animal was used for the 
technique, as was originally suggested by Triguero et al. (1990), whereas the other 
served as tissue input for the biodistribution analysis. After optimization, we found 
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the technique to yield a very robust and reproducible separation of the fractions, and 
analysis of the alkaline phosphatase and g-glutamyl transferase activity underscored 
that the fractions were of high purity. Importantly, it was noted that the separation was 
disturbed if the deceleration of the centrifuge was too fast, and thus, it has been 
stressed in the protocols described in the manuscripts that slow deceleration was 
conditional for a good brain capillary depletion.  
2.3. INDUCTIVELY-COUPLED PLASMA-MASS SPECTROMETRY 
A continuous methodological aspect across the projects described in this dissertation 
is the use of inductively-coupled plasma mass spectrometry (ICP-MS) as the primary 
quantification tool. ICP-MS is known as the most powerful technique for elemental 
analysis in a variety of different sample types. It has been widely used for analysis of 
environmental samples (e.g. water) to study contamination or mineral composition, 
but in the recent years increasing interest has been given to the technique for use 
within biology and life sciences (75, 76). The principle of the technique is a classical 
type filtering based on the atomic mass of a given element and its isotopes using a 
mass spectrometer (77). However, MS is incapable of distinguishing between neutral 
atoms, and hence, an ICP unit is attached to the system to facilitate ionization of the 
sample atoms before entering the mass spectrometer. The plasma inside the ICP unit 
is made of the relatively inert gas, argon, which can create a highly ionized phase at 
extremely high temperatures (6,000 – 8,000°C)(78). 
The sample is introduced into the system via a peristaltic pump attached to an auto 
sampler, from where it is pumped into a nebulizer that converts the fluid into aerosols 
(Figure 2.3.1)(76). This conversion is important since it allows for introducing only 
small volumes into the argon plasma, hereby increasing the plasma stability. Aerosols 
can also be of quite large sizes, which is the reason for nebulizing the sample into a 
spray chamber, where the larger aerosols are restricted from exiting and moving 
further into the system (78). In the ICP unit, a quartz torch inside a copper coil initiates 
the argon plasma by creating a magnetic field that can transfer energy to the argon 
gas. An alternating current (oscillating at 27 or 40 MHz) is produced within the copper 
coil by a radiofrequency generator operated at 1,000 – 1,500 W (76). This induces a 
strong magnetic field at the tip of the quartz torch in which free electrons are produced 
by applying a high voltage spark to the flowing argon gas. These free electrons cause 
collisions and ionization in the argon gas, which produces the plasma. The aerosolized 
sample is then introduced into the plasma with a high velocity that is sufficient to 
‘punch a hole’ through the center of the plasma. Inside the plasma, the aerosols are 
desolvated, vaporized into a gas, and atomized. Lastly, the atoms (originating from 
the sample) are ionized by the plasma and extracted from the plasma chamber to 
continue into the MS unit (Figure 2.3.1)(76-78). 
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Figure 2.3.1. Schematic representation of an inductively-coupled plasma-mass spectrometry system. A 
liquid sample is introduced into an argon plasma after nebulization into small droplets. In the plasma, the 
sample is atomized and ionized. The atomized and ionized sample is extracted from the plasma into the 
mass spectrometry unit, where the pressure in sequentially lowered, and the sample focused using ion 
optics. The focus ion beam is then introduced into the quadrupole mass spectrometer, wherein the trajectory 
of given ions depicts its passage out onto an electron multiplier detector. From here, the signal is extracted 
onto a computer, where the resulting data is analyzed. The figure was re-drawn from Linge et al. (2009)(76). 
In the interface between the high-pressure argon plasma and the ion optics inside the 
MS unit sit two cones responsible for ion extraction and reduction of pressure (78). 
At first, the ions are extracted from the plasma via a sampler cone into a low vacuum 
compartment, thereby reducing the pressure. The extracted ions are then passed 
through a second step of pressure reduction via a skimmer cone, but while this 
effectively reduces the pressure into an intermediate vacuum, it also diverges the ion 
beam substantially (76). Therefore, the ion beam passing the skimmer cone is focused 
via ion optics on its path into the high vacuum chamber, in which the quadrupole mass 
spectrometer is located. Inside the high vacuum chamber, neutral atoms and photons 
are filtered away from the ion beam before the ions left from the initial sample is 
introduced into the mass spectrometer (Figure 2.3.1)(78). In the mass spectrometer, 
the ions are separated based on their mass-to-charge ratio (m/z), which when a certain 
voltage is applied to the quadrupole will allow the ions of interest to oscillate through 
to the detector, whereas extreme oscillations will result in an unstable trajectory for 
other ions, and therefore, these ions are not passed onto the detector (Figure 2.3.2). 
Ions hitting the detector will be counted to yield a total amount of the ion of interest 
in the sample. This can be converted into a concentration of the ion of interest, if a 
standard curve of this ion is generated and measured together with the experimental 
samples (76-78). 
 
Figure 2.3.2. Schematic representation of a quadrupole mass spectrometer. The ion beam from the 
inductively-coupled plasma unit is directed into a quadrupole mass spectrometer, wherein the ions 
originating from the sample will be separated based on their trajectories in the voltage field applied in given 
situations. As such, ions of no relevance will be unstable in the voltage field applied to the quadrupole and 
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collide, whereas the ions of interest with have a stable trajectory throughout the length of the quadrupole 
to be detected on an electron multiplier detector immediately after the quadrupole mass spectrometer.  
ICP-MS was adopted as a quantitative technique due to its very high sensitivity 
compared to other quantitative techniques (e.g. measurements of fluorescence 
intensity). Brain drug delivery is low irrespective of how many folds a given change 
to the drug delivery system improves the transport, and hence, the sensitivity of the 
ICP-MS has been favorable for our purposes. Furthermore, analyzing the presence of 
metals (platinum and gold) as a measure of transport across the BBB also avoids the 
issue of stability/photobleaching, which is an inevitable problem when quantifying 
based on fluorescence (79). In this project, samples taken from tissues, blood, cell 
cultures, and growth medium have been processed and analysed by ICP-MS (49). 
Regardless of the sample origin, processing included complete digestion overnight in 
aqua regia at 65°C followed by dilution in 2 % HCl before analysis. Iridium was 
chosen as an internal standard for both samples, standards, and blanks. This allowed 
for monitoring the stability of the measurements while analyzing 100+ samples per 
run (59, 80). Two points of the standard curve was measured after every ten samples 
to ensure stability of the concentration determination, and extra washing was 
performed between different types of samples (i.e. brain versus liver) to avoid 
spillover. Lastly, to further reduce the risk of spillover and its impact on the 
measurements, samples were analyzed in the order of lowest expected concentration 
to highest expected concentration. 
2.4. SILVER ENHANCEMENT 
Despite using the highly sensitive method, ICP-MS, for the quantitative parts of the 
project, a tool for visualizing the transport of AuNPs across the BBB was needed to 
substantiate the results. For this purpose, the use of electron microscopy (EM) was 
included in some of the projects, because this method allows for very sensitive 
detection of AuNPs located in tissue sections. This method cannot, however, be used 
to investigate larger volumes of brain tissue. Therefore, the silver enhancement 
technique was employed to visualize the colloidal gold in the brain tissue samples 
with light microscopy. The silver enhancement technique is an autometallography 
method, wherein silver ions derived from a silver salt in solution reacts with the 
surface of a nanocrystal (e.g. an AuNP) to adhere and become part of it under catalysis 
induced by a reducing agent (81). In this way, the size of the original colloidal gold 
nanocrystal is increased until reaching the resolution of the light microscope (Figure 
2.4.1)(82). 
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Figure 2.4.1. Schematic representation of the silver enhancement process. Silver enhancement is an 
autometallography technique, where colloidal gold in a tissue sample is developed using silver ions. The 
silver ions and the reducing agent, hydroquinone, is administrated to the sample, which initiates a silver 
deposition process. Colloidal gold can act as a catalyst in this process, and hence, at locations with presence 
of gold, the silver deposition process will be accelerated. This leads to deposition of metallic silver around 
the colloidal gold particles, which with increasing time will develop the original size of the colloidal gold 
particle to reach the resolution limit of either electron microscopy or light microscopy. 
The principle behind the silver enhancement technique was introduced for histology 
by Liesegang in 1911, who took inspiration from the so-called silver-based physical 
developers known from early photography of the 1800s, and wanted to apply this 
principle on tissue specimens (83). Moreover, he wanted to perform silver stainings 
like those Ramón y Cajal used for tissue blocks directly on sections of tissue (83-86). 
His studies showed that this was possible, and hence, he pioneered the use of 
photographic developers for staining purposes on tissue sections, even to such an 
extent that Ramón y Cajal later used his techniques (83, 86).  
Based on work within improvements of photographic plates using silver sulphur 
nanocrystals in the late 1930s (87), Timm (1958) developed a technique in which 
hydrogen sulphide and metal ions (silver) were introduced into a tissue block during 
the fixation process, hereby creating silver sulphur nanocrystals to visualize metals 
contained in the tissue block (88). Later, it was evidenced that most of the silver 
staining could be traced back to zinc (89), which led Timm to develop the method 
further to be able to also visualize mercury in tissue samples exposed to this (90). In 
1981, a Danish group led by Gorm Danscher recognized that if colloidal gold was to 
be detected using silver staining protocols, it was a necessity that the reaction 
happened in a reducing environment, e.g. by exposing the sample to UV light or by 
adding a reducing agent to the silver enhancer solution (91, 92). This sparked the use 
of colloidal gold as labels on antibodies for subsequent use in immunogold labeling, 
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because it became possible to increase the nanocrystal size from below EM resolution 
up to light microscopy resolution (82, 93). Since then, the technique has been used for 
many purposes, which have proven its usability and robustness. For example, AuNPs 
(14.5 nm) were visualized in tissue sections from different organs (94), and the co-
localization of gold and silver in these electron dense spot proven by energy-
dispersive X-ray spectroscopy (EDS)(95). These studies have also found that injected 
AuNPs are cleared from the organism by macrophages in different organs (especially 
the liver and spleen)(96-98), and that gold blocks implanted directly into the brain are 
distributed as nanoparticles in neural and astrocytic processes (99). Similar findings 
will be presented later in this dissertation. Also, several studies employ both the ICP-
MS and silver enhancement techniques to underscore their observations (98, 100). 
In the field of brain drug delivery, the silver enhancement technique has been used on 
several occasions for visualization of AuNPs transported into the brain (100-102). 
Jensen et al. (2013) used the technique to show that injected AuNPs reached the brain 
microvasculature and parenchyma after intravenous injection (100). This 
intraparenchymal location allowed for delivery of RNAi-based medicine to prolong 
the survival of glioma-bearing mice. Others have used the technique more 
quantitatively, where light microscopy assessment and counting of silver-enhanced 
spots (indicative of AuNPs) showed that by modulating the ligand density, the 
transport of AuNPs into the brain parenchyma could be increased (101). The 
methodology was also used to show that a pH-sensitive linker placed between the 
AuNP surface coat (PEG) and the ligand (endogenous transferrin) led to more uptake 
of AuNPs into the brain parenchyma compared to those without this linker (102). Yet 
others used the method to investigate the transcytosis process of OX26 AuNPs (5 nm), 
although these efforts did not result in unambiguous detection of silver-enhanced 
AuNPs in the brain parenchyma (103). In this project, the silver enhancement 
technique was employed on brain tissue sections of a thickness comparable to those 
used by the group of Danscher (97, 104). No quantification was attempted with the 
technique (like performed in the studies presented above), but it was used in 
conjunction with electron microscopy to make visible the observations done using 
ICP-MS after brain capillary depletion. 
2.5. TRANSMISSION ELECTRON MICROSCOPY 
Transmission electron microscopy (TEM) was used in studies related to AuNPs to 
detect the presence of them in the brain capillaries and parenchyma, in addition to the 
ICP-MS-based bulk quantification and silver enhancement of brain tissue sections 
with subsequent light microscopy assessment. The technique was included due to the 
possibility of studying ultrastructure of brain samples from animals having received 
injections with AuNPs, hereby reaching a resolution where individual AuNPs could 
be detected without ex vivo-processing (i.e. using silver enhancement).  
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Figure 2.5.1. Schematic representation of a transmission electron microscope. In a transmission electron 
microscope, electrons are generated from a tungsten or LaB6 crystal filament in the so-called electron gun. 
The electrons are accelerated in vacuum and focused onto the specimen by an electromagnetic condenser 
lens. Electron transmitted through the specimen are further focused using another lens system to generate 
an image on a fluorescent screen, which can be visualized through binoculars, or detected by a CCD camera 
to create digital images. The schematic was re-drawn from Kuntsche et al. (2011)(105), whereas the 
electron microscopy image of neuronal axons was acquired during the PhD course in Electron Microscopy 
at Copenhagen University in 2016. 
The basic principle in TEM is based on exposing a specimen to an electron beam that 
transmits through and becomes detected (Figure 2.5.1)(106). Electrons are generated 
in the so-called electron gun, in which a filament is placed (tungsten or LaB6 crystal) 
that when subjected to a high voltage source releases the electrons into the vacuum of 
the microscope interior. From here, the electrons of the beam are accelerated to obtain 
kinetic energy and focused onto the specimen using a condenser lens made of 
electromagnetic coils (106). When the electron beam reaches the specimen, the 
resulting interaction can induce the formation of several physical phenomena (see 
below), which allows for detection of different kinds of information from the 
specimen. In TEM, the information that is gathered comes from the electrons that have 
been transmitted through the entire thickness of the sample, and hence, it is the density 
of the different components of the specimen (e.g. carbon versus gold) that gives the 
contrast (106-108). However, electrons cannot be transmitted through specimens of a 
large thickness, and therefore, tissue and cell samples analyzed with TEM must be 
sectioned to a thickness of 80 – 150 nm for the electrons to pass through (107, 109). 
The electrons that pass through the sample are guided further down the TEM column 
via another lens system (including objective lens and projector lens) to project the 
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image of the sample onto a fluorescent screen, wherefrom the sample can be 
visualized using binoculars. The sample can also be projected to a charge-coupled 
device (CCD) camera to acquire images (Figure 2.5.1)(106). To enhance the contrast 
in the sample, the thin sections are stained using heavy metals such as lead, osmium 
and uranium before imaging. These compounds will scatter the electrons of the beam 
to yield a grey-toned appearance, e.g. of lipid rich structures such as cell membranes 
in the case of osmium. The resulting image can then be analyzed for its information 
on the ultrastructure of the sample in question, although interpretations will have to 
regard the fact that the sample processing procedure include both dehydration and 
resin embedding, which could have detrimental effects on the size of extracellular 
spaces, cell organelles, or the entire cell itself (110). Still, TEM provides for the best 
resolution compared to other microscopy techniques, and will thus be fit for many 
purposes. 
 
Figure 2.5.2. Electron microscopy images showing the presence of a salt artefact inside a neural process. 
(A) A salt crystal was observed inside a neural process closely resembling a gold nanoparticle. Therefore, 
without further processing, such an artefact would likely be interpreted as a gold nanoparticle having 
traversed the blood-brain barrier. (B) The same salt artefact could be pierced by a high intensity, focused 
electron beam, which proved it to be an artefact and not a gold nanoparticle, which would make the primary 
interpretation (without additional analysis using energy-dispersive X-ray spectroscopy) false. 
TEM has served as a valuable tool because of its potential for studying ultrastructure 
of the nanoparticle-treated brain samples, which furthermore allowed for visualization 
of individual nanoparticles instead of measuring bulk quantities as with ICP-MS (75). 
It is well known that electron microscopy can resolve the presence of nanoparticles in 
tissues, but even though it is easy to see highly electron dense nanoparticles (i.e. 
AuNPs), processing of the tissue before the microscopic analysis can induce different 
types of artefacts that are likely to be interpreted as nanoparticles (Kempen et al., in 
preparation). To illustrate this issue, we analysed sections from mice that had received 
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no treatment with AuNPs, but had been exposed to the same kinds of tissue processing 
for subsequent electron microscopy (Figure 2.5.2A). Using TEM, it was evident that 
electron dense, punctate structures could be observed in the brain parenchyma, even 
though no AuNPs were injected into the animal (Figure 2.5.2A). Such structures are 
likely interpreted as successfully transcytosed nanoparticles, because it is very 
difficult to claim it to be anything else, when analyzing a sample where AuNPs were 
in fact injected. One way to resolve this is to boost the electron beam and focus this 
on the electron dense structure in question (Figure 2.5.2B). This will for AuNPs not 
lead to any adverse effects (although it might harm the sample), and so, the AuNP 
integrity will be preserved. However, for artefacts like salt precipitates induced during 
the processing, it will be possible to partly destroy it (Figure 2.5.2B, hole in the middle 
of the salt artefact). While this technique is a pragmatic solution to study the presence 
of true AuNPs in the brain parenchyma, it will probably result in sample destruction, 
which will not be applicable for routine analysis of the AuNPs in a sample. 
2.6. ENERGY-DISPERSIVE X-RAY SPECTROSCOPY 
We instead utilized the microanalysis technique, energy-dispersive X-ray 
spectroscopy (EDS), for element composition microanalysis of the tissue samples 
analysed using TEM. As depicted by its name, the principle of this technique is based 
on the early work of Wilhelm Röntgen on a new type of rays (Röntgen rays or X-rays), 
which earned him the Nobel Prize in 1901 (111, 112). Later, the work of Charles G. 
Barkla showed that the X-rays emitted from a sample is connected to the atomic 
weight of the elements contained in the sample (113-118), which was further 
expanded by Henry G. J. Moseley, who explained how the so-called K-line transitions 
(movement of electrons between different energy states) moved the same amount in 
the X-ray spectrum, when the atomic number increased by one (119-123). Combined, 
these observations led to the invention and commercialization of the first X-ray 
spectrometers in the late 1950s, which were the foundations for the energy-dispersive 
X-ray spectrometers used in connection to TEM today (124).  
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Figure 2.6.1. Schematic representation of the process in energy-dispersive X-ray spectroscopy. When an 
electron interacts with a specimen, it can yield a so-called characteristic X-ray, which gives information 
about the elemental composition in the specimen. This X-ray can be detected and processed to give an 
element spectrum. The schematic was re-drawn from Kuntsche et al. (2011)(105), and the elemental 
spectrum was derived from Corbari et al. (2008)(125). 
The information acquired using EDS is based on the physics of electrons interacting 
with the specific atoms of a given sample (126, 127). As depicted in a simple 
schematic in Figure 2.6.1, electrons are accelerated inside the column of an electron 
microscope, hereby obtaining kinetic energy. The high-energy electrons are focused 
on the sample, where it interacts to generate different phenomena, which for the sake 
of EDS is an X-ray of a specific energy corresponding to the elemental composition 
of the sample. These X-rays are measured on a detector, wherefrom the information 
is processed and mapped to yield an element spectrum of the entire sample or a region 
of interest in the sample (Figure 2.6.1). 
 
Figure 2.6.2. Schematic representation of the interaction between an electron beam and a specimen. When 
electrons hit a specimen, it can result in generation of many different phenomena. In TEM, it is the 
transmitted electrons that are detected and used from image acquisition. However, important for the energy-
dispersive X-ray spectroscopy technique are the X-rays generated in the same process. By in-elastic or 
elastic scattering of the incoming electrons, an X-ray continuum, known as brehmsstrahlung, is generated. 
These X-ray does not carry any information on the elemental composition of the specimen. Conversely, 
generation of so-called secondary electrons can result in the generation of so-called characteristic X-rays 
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that are specific to the element contained in a specific region of the specimen. These can be detected in 
energy-dispersive X-ray spectroscopy. The schematic is re-drawn from Vaughan (2008)(126). 
Looking at the process at an atomic level, the beam of electrons can interact with the 
sample in several ways (for the purpose in this section, the interactions are only 
summarized in Figure 2.6.2). Electrons moving close to the atomic nucleus can have 
their trajectory bend in the coulomb field, such that it will scatter either elastically or 
inelastically (Figure 2.6.3A). For the inelastically scattered electron, this process will 
slow the electron passing through the sample by loss of kinetic energy, and this energy 
will be emitted as an X-ray continuum known as bremsstrahlung (Figure 2.6.3A). This 
X-ray continuum cannot be traced back to determine the specific elemental 
composition of the sample.  
 
Figure 2.6.3. Schematic representation of an electron interacting with an atomic nucleus. When an electron 
hits a specimen inside a transmission electron microscope, different kinds of X-rays can be generated. (A) 
The electrons can be scattered by the atomic nucleus inelastically to generate an X-ray continuum, which 
is known as brehmsstrahlung. Such radiation does not carry information about the specific element. (B) In 
another situation, the incoming electron can eject an electron from the electron shells of the atom as a so-
called secondary electron. (C) This leaves a void, wherein electrons from the outer shells can move to. In 
this process (which transfers the ion from an excited state to the ground state), the outer shell electrons must 
give up a part of its energy as X-rays of a specific energy, which can be detected as characteristic X-rays. 
This yields information about the elemental composition of the specimen, since the amount of energy is 
different for each element of the periodic table. The schematic is re-drawn from Vaughan (2008)(126). 
In addition, the high-energy electrons of the electron beam can interact with an 
electron in the inner atomic shell to eject this as a so-called secondary electron (Figure 
2.6.3B). This yields an ion in an excited state with a void in which another electron 
can move to. For the ion to return to its ground state, an electron from an outer shell 
must transition into the void created by the ejection of the secondary electron (128). 
The electron transitioning must give up some of its energy to drop into the void, and 
this energy is emitted as electromagnetic radiation X-rays (Figure 2.6.3C). These X-
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rays (or the amount of energy/the wavelength that characterizes them) are specific for 
each element in the periodic table, and hence, can be processed to give information 
about the composition of the sample (126, 128). In EDS, the energy of the X-rays is 
analyzed as opposed to the analogous technique, wavelength-dispersive spectrometry, 
where the wavelength of the emitted X-rays is analyzed (126, 127). 
EDS proved to be an important method to use in the study of AuNP transport into the 
brain. As described above, salt artefacts in the brain parenchyma can easily be 
interpreted as transcytosed AuNPs, if that is what one is looking for in the tissue. 
Therefore, we chose to analyze all potentially transcytosed AuNPs with EDS to ensure 
that they were in fact gold, and not just salt artefacts. EDS was also used to determine 
the presence of gold in some of the AuNPs found in brain capillaries, however, the 
large number of these observations (i.e. correlating with the observed upconcentration 
of AuNPs in the brain capillaries by ICP-MS) made it impossible to do this analysis 
as a standard for all of them. Nevertheless, EDS is a very advanced technique not 
accessible for many brain drug delivery groups, and as such, the use of this technology 
is an improvement with respect to TEM interpretations with high validity. 
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CHAPTER 3. OBJECTIVES OF THE DISSERTATION 
Based on the literature review presented in Manuscript I and Manuscript II, we find 
that while transferrin receptor-targeting has been pursued for brain drug delivery in 
well over two decades, there has still not been any real progress with respect to clinical 
translation of the preclinical findings. For example, the phenotype has been corrected 
in many animal models of brain disease via delivery of drugs through transferrin 
receptor-targeted fusion constructs or nanomedicines, but it does not seem to hold 
true, when more structured preclinical or clinical testing is performed. Thus, there 
must be aspects of this drug delivery strategy that we still do not understand: 
- Are nanoparticles being transported across the blood-brain barrier into the 
brain parenchyma? 
 
- Is it only an encapsulated cargo that can be transported into the brain 
parenchyma after intracellular processing of a nanoparticle? 
 
- How does ligand affinity impact the uptake of nanoparticles into the brain 
parenchyma? 
 
- How does ligand valency impact the uptake of nanoparticles into the brain 
parenchyma? 
 
- How does total ligand density impact the transport of solid nanoparticles into 
the brain parenchyma, and is this impact different from that of an 
encapsulated cargo? 
 
- How do nanoparticles behave in the brain compartment after direct 
administration? 
These questions will be sought answered in Chapter 4 based on the methodology 
presented in Chapter 2. 
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4.1. MANUSCRIPT III 
Targeting transferrin receptors at the blood-brain barrier improves the uptake of 
immunoliposomes and subsequent cargo transport into the brain parenchyma 
Kasper Bendix Johnsen1,2, Annette Burkhart1, Fredrik Melander2, Paul Joseph 
Kempen2, Jonas Bruun Vejlebo2, Piotr Siupka3, Morten Schallburg Nielsen3, Thomas 
Lars Andresen2 & Torben Moos1* 
1Laboratory for Neurobiology, Biomedicine, Institute of Health Science and 
Technology, Aalborg University, Aalborg, Denmark. 2Center for Nanomedicine and 
Theranostics, Department of Micro- and Nanotechnology, Technical University of 
Denmark, Denmark. 3Department of Biomedicine, Aarhus University, Denmark. 
Manuscript published in Scientific Reports 
Abstract 
Drug delivery to the brain is hampered by the presence of the blood-brain barrier, 
which excludes most molecules from freely diffusing into the brain, and tightly 
regulates the active transport mechanisms that ensure sufficient delivery of nutrients 
to the brain parenchyma. Harnessing the possibility of delivering neuroactive drugs 
by way of receptors already present on the brain endothelium has been of interest for 
many years. The transferrin receptor is of special interest since its expression is limited 
to the endothelium of the brain as opposed to peripheral endothelium. Here, we 
investigate the possibility of delivering immunoliposomes and their encapsulated 
cargo to the brain via targeting of the transferrin receptor. We find that transferrin 
receptor-targeting increases the association between the immunoliposomes and 
primary endothelial cells in vitro, but that this does not correlate with increased cargo 
transcytosis. Furthermore, we show that the transferrin receptor-targeted 
immunoliposomes accumulate along the microvessels of the brains of rats, but find 
no evidence for transcytosis of the immunoliposome. Conversely, the increased 
accumulation correlated both with increased cargo uptake in the brain endothelium 
and subsequent cargo transport into the brain. These findings suggest that transferrin 
receptor-targeting is a relevant strategy of increasing drug exposure to the brain. 
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4.2. MANUSCRIPT IV 
Antibody affinity and valency impact the brain uptake of transferrin receptor-
targeted gold nanoparticles 
Kasper Bendix Johnsen1,2, Martin Bak2, Paul Joseph Kempen2, Fredrik Melander2, 
Annette Burkhart1, Maj Schneider Thomsen1, Morten Schallburg Nielsen3, Thomas 
Lars Andresen2* & Torben Moos1* 
1Laboratory for Neurobiology, Biomedicine, Department of Health Science and 
Technology, Aalborg University, Aalborg, Denmark. 2Center for Nanomedicine and 
Theranostics, Department of Micro- and Nanotechnology, Technical University of 
Denmark, Denmark. 3Department of Biomedicine, Aarhus University, Denmark. 
Manuscript submitted to Science Advances 
Abstract 
The ability of treating invalidating neurological diseases is impeded by the presence 
of the blood-brain barrier (BBB), which inhibits the transport of most blood-borne 
substances into the brain parenchyma. Targeting the transferrin receptor (TfR) on the 
surface of brain capillaries has been a popular strategy to give a preferential 
accumulation of drugs or nanomedicines, but several aspects of this targeting strategy 
remain elusive. Here we report that TfR-targeted gold nanoparticles (AuNPs) can 
accumulate in the brain capillaries and transport across the BBB to enter the brain 
parenchyma. We find that this uptake capacity is significantly modulated by the 
affinity and valency of the AuNP-conjugated antibodies. Specifically, antibodies with 
high and low affinities mediate a low and intermediate uptake of AuNPs into the brain, 
respectively, whereas a monovalent (bi-specific) antibody improves the uptake 
capacity remarkably. We characterize this concept both in vitro using primary models 
of the BBB and in vivo using quantitative measurements of gold accumulation 
together with morphological assessments using light and transmission electron 
microscopy. Our findings indicate that monovalent ligands may be beneficial for 
obtaining transcytosis of TfR-targeted nanomedicines across the BBB, which is 
relevant for future design of nanomedicines for brain drug delivery. 
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4.3. MANUSCRIPT V 
Modulating the ligand density changes the brain uptake of transferrin receptor-
targeted gold nanoparticles and liposomal cargo 
Kasper Bendix Johnsen1,2, Martin Bak2, Paul Joseph Kempen2, Fredrik Melander2, 
Maj Schneider Thomsen1, Annette Burkhart1, Thomas Lars Andresen2 & Torben 
Moos1* 
1Laboratory for Neurobiology, Biomedicine, Department of Health Science and 
Technology, Aalborg University, Aalborg, Denmark. 2Center for Nanomedicine and 
Theranostics, Department of Micro- and Nanotechnology, Technical University of 
Denmark, Denmark. 
Manuscript in preparation 
Abstract 
Transport of therapeutic molecules to the brain is largely precluded by the presence 
of the blood-brain barrier (BBB), hereby rendering efficient treatment of neurological 
disorders impossible. The BBB may be circumvented by targeting the drug towards 
receptors and transport proteins expressed on the surface of the brain capillary 
endothelial cells (BCECs). The transferrin receptor (TfR) has remained a popular 
target since its original description for this purpose, although clinical progression of 
TfR-targeted drug constructs or nanomedicines has yet to be seen. On proposed issue 
pertaining to the use of TfR-targeting in nanomedicines has been the efficient tuning 
of the ligand density on the nanoparticle surface. In this study, we studied the impact 
of ligand density on the transport of nanoparticles into the brain, taking a parallel 
approach to investigate the impact on both antibody-functionalized gold nanoparticles 
(AuNPs) and cargo-loaded liposomes. We find that among three different low-range 
ligand densities (0.15, 0.3, and 0.6 * 103 antibodies/µm2), the highest density yielded 
most targeting abilities towards the BCECs and subsequent transport across the BBB 
in vitro and in vivo. Furthermore, we find that TfR-targeting on nanoparticles may 
induce severe adverse effects after intravenous administration. 
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4.4. MANUSCRIPT VI 
The surface charge depicts the brain distribution of liposomes after 
intracerebroventricular administration – a morphological study 
Kasper Bendix Johnsen1,2, Jonas Bruun Vejlebo2, Thomas Lars Andresen2 & Torben 
Moos1* 
1Laboratory for Neurobiology, Biomedicine, Department of Health Science and 
Technology, Aalborg University, Aalborg, Denmark. 2Center for Nanomedicine and 
Theranostics, Department of Micro- and Nanotechnology, Technical University of 
Denmark, Denmark. 
Manuscript in preparation 
Abstract 
Transport of intravenously administrated drugs into the brain is obstructed by the 
blood-brain barrier, which constitutes the interface between the systemic circulation 
and the fragile brain parenchyma. Many variants of nanomedicines have been 
developed for being transported into the brain, but despite employing different 
targeting strategies and controlled release mechanisms, none of these nanomedicines 
have reached the clinical stages of drug development. A solution to this issue may be 
to administrate the nanomedicine directly into the brain compartment, although drug 
delivery via this route is still poorly investigated. Here we investigated the distribution 
of liposomes after intracerebroventricular administration. We find that liposomes with 
either anionic and cationic surface charge are efficiently transported to the 
subarachnoid space after intracerebroventricular administration, and that much of the 
liposome dose is taken up by resident macrophages. Additionally, we observe a 
marked difference in cortical penetration, where anionic liposomes penetrate deeply 
into the brain cortex along the penetrating arteries, whereas the depth of penetration 
was much lower for cationic liposomes. These findings suggest that an anionic surface 
charge is favourable for obtaining a good cortical distribution of administrated 
liposomes. 
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CHAPTER 5. JOINT DISCUSSION 
Based on the findings of the literature and experimental projects presented in 
Manuscript I – VI, this chapter will be devoted to a joint discussion of all projects. 
While there has been discussions of the different aspect of both the literature reviews 
and experimental results in the respective manuscripts, this joint discussion seeks to 
draw some broader lines and describe some interesting similarities and differences 
between the studies. The main focus is on the findings made in Manuscript III – IV, 
since these projects were all focusing on different aspects pertaining to the use of the 
TfR as a target for nanomedicine-based brain drug delivery. Furthermore, several 
discussion points of the literature reviews in Manuscript I – II are revisited and 
updated with the most recent literature. Further discussion of the findings in 
Manuscript VI is omitted, since this project stood out with a markedly different 
purpose than the other projects. The reader is thus referred to the discussion presented 
in this manuscript itself. 
5.1. CURRENT STATUS OF BRAIN DRUG DELIVERY VIA 
NANOMEDICINES 
Despite the large focus on brain diseases impacting the health on an aging population, 
there is still a lack of medicines that can combat them. However, when looking at the 
number of FDA approvals for neurology, there seems to be no paucity of therapies 
getting available for use in the clinic, as has been argued by many (129), when 
compared to other types of diseases within oncology and cardiology (Figure 5.1.1). 
The drugs that are approved are often for use against pain or against symptoms of 
neurodegenerative disorders rather than the disease mechanisms per se. Also, many 
of the approvals are for small molecule drugs, which means that the great promise of 
the biological treatments (i.e. antibody-based) has yet to come forth. This was 
illustrated in the case of solanezumab by Eli Lilly, a monoclonal antibody against b–
amyloid, which attracted worldwide media attention in 2015 due to findings of 
delayed disease progression in a subgroup of patients suffering only from mild 
Alzheimer’s disease (130-133). However, when a Phase III clinical trial was 
performed to study this patient group only, the original findings were not supported 
at primary endpoint analysis, which led to the termination of the so-called 
EXPEDITION3 trial (133-136). Such outcomes from clinical trials are unfortunate, 
but not rare. A 2014 paper calculated the failure rate of drugs for Alzheimer’s disease 
to be 99.6 % (both antibody-based and small molecules)(137). Another striking fact 
is that in the current pool of clinical trials, most of the drugs studied target the b–
amyloid protein present in the brain parenchyma, but provide no means of transport 
into the brain (138). Clinical trials using nanomedicines are rare, and they most often 
study brain tumors or brain metastases in very small populations (139). Thus, it seems 
that a burning platform exists for including BBB transport strategies for future drugs 
in development to improve the current success rate.  
CHAPTER 5. JOINT DISCUSSION 
47 
 
Figure 5.1.1. Overview of the number of FDA-approved drugs between 1997 and 2017.  
Based on this burning platform, a vast variety of brain drug delivery strategies has 
been developed over the past decades, especially nanomedicines strategies that have 
a theoretical potential of delivering large payloads of drugs to the brain parenchyma, 
if the nanoparticles are designed to cross the BBB (140, 141). The development of 
these BBB-passing nanomedicines has not yet amounted into true clinical progress, 
and as such, the fate of most new nanomedicine designs resembles that of small 
molecule drugs or biologicals, namely that most of them will fail (140). In principle, 
this is not problematic as this is the normal path in drug development (142). However, 
for brain drug delivery, the use of nanomedicines has shown to be particularly poor 
with respect to clinical translation, leaving no true examples of its clinical utility until 
now (141). Since no critical assessments of the current status on nanomedicines for 
the treatment of brain diseases are available in the literature, one can turn towards the 
nanomedicine field as a whole.  
In the recent years there have been an increased recognition in the field of 
nanomedicine that much of the potential of these strategies for the treatment of 
diseases (cancer in particular) rely on several unvalidated assumptions, and that the 
downstream experimentation is flawed by confirmation bias related to these 
assumptions (143, 144). One prominent example of such an assumption is the 
universal presence of the so-called enhanced permeation and retention (EPR) effect 
as a positive driver of tumor accumulation of nanoparticles, leading to increased drug 
exposure and therapeutic efficacy (145). While there are numerous cases of evidence 
to suggest a role for the EPR effect in preclinical models of malignant diseases, the 
impact of the effect in clinical trials seems limited at most (146). This was especially 
evident in a recent meta-analysis of available preclinical and clinical studies on the 
use of liposomal doxorubicin, which showed a markedly improved efficacy of this 
chemotherapeutic drug in solid tumors compared to the free drug in preclinical 
models, whereas meta-analysis of the clinical evidence showed no effect at all (147). 
Leading researchers of the nanomedicine field even state that there has been no 
clinical progression at all despite clinical approval of a few formulations, because 
most of these do not present with a better therapeutic efficacy (143, 148). This lack of 
clinical progression is discussed to be due to poor disease modelling in preclinical 
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studies, and relying too much on the EPR effect for the therapeutic efficacy, when 
increasing amounts of evidence suggest that it is not a universal phenomenon (145, 
149). Poor understanding of the drug release kinetics, uptake into tumor cells, and 
distribution within the tumor tissue compartment is another problematic aspect in the 
current nanomedicine strategies. Also, there have been no limitations of the peripheral 
accumulation in the liver, spleen, and lungs, which upholds an unfavorable adverse 
effect profile of the developed nanomedicines (143). In general, it seems that many of 
the problems related to the development of efficient nanomedicines (for cancer 
treatment) are due to a poor understanding of or lack of interest in considering the 
complex disease biology and the fact that all tumors are unique (143, 145, 150). Thus, 
if all preclinical development focuses on the limiting the variability (in homogenous 
animal disease models) to increase the chance of success, then the downstream clinical 
potential may in fact be reduced substantially. For clinical progression of 
nanomedicines, there must be considerations of many other aspects than what is 
currently included in experiments (142). 
Returning to the use of nanomedicines for brain drug delivery, several of the 
problematic features described above seem to apply here as well. First, many studies 
of nanomedicine-based brain drug delivery disregard the potential diminishing aspects 
of the strategy, such as unfavorable accumulation in peripheral organs or hemolysis 
when in circulation. This likely follows the logic that if the improvement is large 
enough, e.g. with respect to cognitive performance in Alzheimer’s disease patients, 
then the potential adverse effects can be tolerated (140). However, at this point, 
nothing suggests that such large improvements in disease-related parameters are to be 
expected. Second, in studies of brain drug delivery (clinical or preclinical), there is a 
general lack of understanding of the amount of drug that reaches the brain 
parenchyma, and what fraction of this that will be unbound and available for eliciting 
its therapeutic effect (151). Furthermore, the extent of distribution inside the brain 
parenchyma after effective BBB transport is also not understood. This means that even 
though we are able to transport therapeutic compounds across the BBB, we cannot yet 
correlate this with the amount of therapeutic efficacy that is to be expected, because 
the aspect of dosing and drug distribution is so poorly studied. Interestingly, though, 
there are now indications that encapsulation of a drug in a liposome is enough to 
increase brain exposure, because this encapsulation will improve the circulatory half-
life of the drug and avoid unspecific binding with components of the blood (74, 152-
154). Follow-up studies on this concept will likely improve our understanding of the 
extent of which BBB transport of nanomedicines can be viable for effective treatment 
of disease processes in the brain parenchyma, or whether the same effects can be 
achieved by better circulation properties (73, 74, 152, 154). Third, the field of 
nanomedicine-based drug delivery also build its potential of largely unvalidated 
assumptions, including that the BBB will be open for passive accumulation of 
nanoparticles as a result of neurodegenerative or neuromalignant disease (see 
below)(155-157), or that specific target receptors are said to be transcytosing (often 
stated by brain drug delivery researchers), while this does not follow the 
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normophysiological sorting of these receptors (as described by researchers in BBB 
cell biology and biochemistry)(158). Fourth, the brain drug delivery field is (like 
many other research fields) severely impacted by poor animal models used to describe 
the downstream clinical potential (140, 159, 160). This is especially problematic for 
a range of neurodegenerative diseases, which can be modelled to some extent in 
rodents, e.g. to observe overexpression of disease-related proteins or ongoing 
neuroinflammation. However, the human-associated symptomatology is rarely 
observed, because rodents do not have analogous neurodegenerative diseases because 
of their short lifespan (140, 161, 162). 
How to progress from this state of poor translational value of currently available 
nanomedicine strategies for brain drug delivery is difficult to resolve at this point. It 
will likely have to encompass much deeper considerations of the end-point that is 
targeted, e.g. a relevant drug concentration needed to be obtained within a certain 
time-frame to induce therapeutic effects inside the brain parenchyma. The same is true 
for the choice of target, where just choosing a relevant one is now the strategy of the 
past, in favor of more detailed studies of how the nanomedicine (and targeting ligands) 
can interact with the receptor of choice, and what parameters that can be modified to 
control both the interaction and the sorting/transport processes (49, 141, 163). 
5.2. IS THERE A NEED FOR TRANSPORT ACROSS THE BLOOD-
BRAIN BARRIER? 
There is still great dispute regarding the possible loss of BBB integrity in 
neurodegenerative and neuromalignant disorders, and the possibility that an 
intravenously administrated drug or nanomedicine will reach the brain parenchyma 
due to this loss of integrity (156, 157, 164, 165). In Manuscript I and Manuscript II, 
this issue was discussed in depth in relation to the impact it may have on nanoparticle 
accumulation in the brain parenchyma, and how this disruption may leave strategies 
to overcome the BBB with nanoparticles or drug constructs irrelevant (141, 163). 
Here, a few points of this discussion are revisited and updated with newer references 
to highlight the main arguments for continuing the work on targeted nanoparticle 
strategies for transport across the BBB. 
Many neurodegenerative disorders have been characterized with an impacted BBB, 
including Alzheimer’s disease (166, 167), Parkinson’s disease (168-170), 
Huntington’s disease (171), multiple sclerosis (155, 156, 172), cerebral malaria (173), 
and glioblastoma multiforme (157). Investigations into the impact of such a loss of 
integrity have shown passive accumulation of drugs or blood constituents in the 
diseased area (167, 168, 170), which indicates that the brain parenchyma is readily 
accessible from the systemic circulation, but it also raises the opportunity of getting 
preferable drug accumulation at the site, where it is needed (174). This was especially 
evident in a series of paper showing passive accumulation of drugs encapsulated into 
stealth-like (non-targeted) liposomes in multiple models of human neurodegenerative 
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disease, including the experimental autoimmune encephalomyelitis (EAE) model of 
multiple sclerosis (155, 173, 175-177). However, the EAE model is known to have a 
very impaired BBB, which does not readily mimic the level seen in human disease or 
other neurodegenerative diseases (156), which decreases the translational value of 
these findings.  
 
Figure 5.2.1. The theoretical impact of BBB disruption for brain delivery of nanomedicines. The figure 
describes the potential for transport of nanoparticles (green) into the brain parenchyma during 
neurodegenerative disease suggested by either (A) Bien-Ly et al. (2015)(156) or (B) Turjeman et al. 
(2015)(155). 
The BBB disruption (including the increased permeability of newly formed vessels 
observed in several diseases) and its impact on disease progression was also 
highlighted in many studies based on both preclinical (168, 169, 171, 178-185) and 
clinical data (164-167, 186), although data on its impact on drug delivery is still scarce 
(for a detailed review, please refer to Obermeier et al. (2013)(164) or Zhao et al. 
(2015)(165)). BBB disruption seems to correlate with increasing age in humans, and 
not only with progressing neurodegenerative disease (166). Interestingly, such 
breakdown of the BBB was correlated with increasing amounts of extravasated IgG 
in the hippocampal area of the brain during Alzheimer’s disease, suggesting that the 
opening is rather prominent, and that the disruption may aggravate with progressing 
disease (164, 165, 167). Still, in the case of solanezumab explained above, those 
patients with late-stage Alzheimer’s disease had a very poor therapeutic response to 
the treatment. If we assume that target of solanezumab was indeed relevant for these 
patients, this indicates that regardless of the presence and magnitude of BBB 
disruption in these patients, it was not enough to obtain a therapeutically relevant 
dosage of IgG in the brain parenchyma (i.e. hippocampus). This was underscored in 
another series of studies in multiple preclinical models of Alzheimer’s disease, where 
BBB opening even to small molecule drugs (266 – 720 Da) or dextrans (3 kDa) was 
insignificant (156, 187-191), and where increased intraparenchymal IgG 
concentrations could be obtained only if they were endowed with capacity to target 
and transport with the TfR (156). Together, these findings, both preclinical and 
clinical, indicate that disruption of the BBB may indeed be a factor in most brain-
related disorders, but the magnitude of this disruption is still difficult to decipher. 
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Even though clinical data exist on significant opening of the BBB, e.g. in Alzheimer’s 
disease, its utility with respect to increasing drug exposure seems largely unresolved, 
if existing at all. This was demonstrated in a recent review of BBB disruption in 
glioblastoma multiforme (157). Here, it was argued that even though BBB disruption 
is evident in this disease (like the general increased vascular permeability in many 
cancer types), it is non-uniformly distributed with large areas of maintained or 
increased integrity. This correlates with poor uptake of even small chemotherapeutics 
in many regions of the tumor and subsequent poor therapeutic outcome for the patient 
(157). Moreover, even in cancer, where there is a high chance of passive accumulation 
due to increased leakiness of the tumor vasculature, it can be difficult to obtain drug 
accumulation at a level more than 0.7 %ID (148). There is thus still a clear reason to 
study drug delivery strategies that can overcome the BBB and gain access to the brain 
parenchyma. 
In this dissertation, a choice was made to study only healthy animals when assessing 
the transport capacity of the different nanoparticle strategies developed. This had 
several advantages, including the ease and lower cost of performing large-scale 
studies and performing studies in models where the receptor systems were expected 
to behave ‘normally’. In Manuscript III, we chose to study the uptake of OX26 
immunoliposomes in young rats. The choice of using young rats instead of adults was 
based on the evidence that the expression of TfRs is high during development (65), 
which could increase the likelihood of interaction between the TfR and OX26 
immunoliposomes. In Manuscript IV and Manuscript V, the female mice used for the 
assessment of AuNP and liposome transport into the brain were also considered to be 
young of age (approximately 8 weeks by the time of experiments)(192). The choice 
of age was made to mimic that of the published papers that our work was inspired by, 
namely that of Yu et al. (2011)(193) and Wiley et al. (2013)(107). Especially, we 
figured that to study the aspects of antibody affinity and valency on the transport of 
AuNPs into the brain (Manuscript IV), the most proper choice of experimental setup 
was one like Yu et al. (2011)(193), since we used the antibodies developed in this 
study. Thus, in all studies of this dissertation concerning the use of targeted 
nanoparticles for brain drug delivery, we used ‘prime’ animals that were healthy and 
young, and were expected to have no changes in their BBB integrity or receptor 
transport pathways. 
It is indeed a limitation in our studies that we do not consider modelling of the brain 
disease, for which our nanomedicine strategy would be relevant to use. This means 
that the possibility of BBB disruption as an additive factor in the accumulation on 
nanoparticles was not tested in our setup, and thus, the studies presented in this 
dissertation can only provide knowledge on the transport across the properly 
maintained BBB, but not the full scale of nanoparticle accumulation in a state of 
neurodegenerative or neuromalignant disease. It would, however, be highly relevant 
to test this hypothesis in preclinical models of brain disease, to gain knowledge about 
how a disruption would impact the nanoparticle accumulation. 
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5.3. BIODISTRIBUTION ANALYSES 
Accumulation of nanoparticles in peripheral tissues are expected after intravenous 
administration (148), especially in cases of brain drug delivery where only a very 
small fraction of the injected dose reaches the area of interest (< 1 %ID)(141, 163). 
This process of unspecific accumulation, despite targeting qualities etc., has been 
studied greatly in the last two decades. The efforts have shown that both the liver and 
spleen are preferable sites of accumulation of nanoparticles, mostly because the 
injected nanoparticles are opsonized by serum proteins in the systemic circulation and 
subsequently cleared by resident macrophages (194, 195). This happens instantly after 
injection, hereby leaving only little left of the dose to interact with the target (196-
198). These findings have paved the way of designing nanoparticles that are able to 
avoid this clearance, e.g. by mimicking the surface of a red blood cells or surface 
coating the nanoparticles with polymers such as PEG (199). The creation of a so-
called protein corona has also been described for such surface-coated nanoparticles, 
which could decrease the targeting qualities of conjugated ligands, and in general 
reduce the circulatory half-life of the nanoparticles (200-204). The impact of this 
protein corona is, however, still heavily debated, because newer findings suggest that 
the total number of proteins that can interact with and bind to a PEGylated 
nanoparticle surface is low, and thus, only impacts the targeting qualities of the 
nanoparticles very little (205). Regardless of the magnitude of the impact, there is 
little doubt that most of an injected dose of nanoparticles will accumulate in other 
tissues than the brain. 
Biodistribution analysis was performed in all studies that utilized the intravenous 
administration route presented in this dissertation (summary presented in Figure 
5.3.1). The choice of including the analysis was the logical consequence of the issue 
presented above, namely that most of the injected liposomes and AuNPs were 
expected to accumulate other places than the brain (163). Across these studies of TfR-
targeted liposomes or AuNPs, there seemed to be a clear tendency that most of the 
injected dose would end up in either the liver or the spleen. Still, we observed that 
while the accumulation of nanoparticles in the liver did not correlate with the TfR-
targeting, the splenic accumulation of nanoparticles did. In Manuscript III, isotype 
IgG and OX26 immunoliposomes were compared in the rat, showing that there was 
no difference in the uptake in the liver after 1 hour of circulation. In the spleen, isotype 
IgG immunoliposomes accumulated at a level of approximately 10 %ID/g, whereas 
this accumulation was three-fold higher for the TfR-targeting, OX26 
immunoliposomes (approximately 30 %ID/g). In Manuscript IV, mPEG AuNP 
accumulation in the liver was lower than that of protein (i.e. antibody)-functionalized 
AuNPs, including isotype IgG AuNPs, indicating no effect of TfR-targeting on liver 
accumulation. Conversely, the two high-affinity-binding variants of TfR-antibodies 
(anti-TfRA and anti-TfRA/BACE1) increased the splenic accumulation to 25 – 40 
%ID/g, much higher than the accumulation observed for the mPEG and isotype IgG 
control AuNPs (10 – 13 %ID/g). In Manuscript V, there was no difference between 
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mPEG and TfR-targeted AuNPs with respect to liver accumulation, but in the spleen, 
the accumulation seems to correlate with increasing amounts of anti-TfR antibodies. 
For the liposomes, a somewhat low liver accumulation was observed with no 
differences between the individual groups, whereas increased splenic accumulation 
was observed for all TfR-targeted variants. Importantly, in this study, there were no 
isotype IgG control nanoparticles included, which make clear-cut interpretations of a 
TfR-mediated accumulation difficult. Nevertheless, in combination, the observations 
made in these three studies clearly indicate that splenic accumulation of nanoparticles 
are reinforced by targeting the TfR. 
 
Figure 5.3.1. Overview of the sites of peripheral accumulation after intravenous administration of 
nanoparticles. High levels of accumulation (green) were observed in both the liver and the spleen. In the 
spleen, there was also a tendency of improved accumulation as a function of TfR-targeting. Intermediate 
levels (yellow) of accumulation were observed in the lungs and the kidneys. 
TfR expression is present both in the liver and spleen (Figure 5.3.2). In the liver, the 
TfR expression has been described both for the hepatocytes and Kupffer cells (both 
TfR1 and TfR2) with subcellular localization both in the cytoplasm and cell 
membrane (206-209). Thus, in principle, the nanoparticles injected in the studies 
presented in this dissertation could accumulate in the liver via the TfR. However, as 
presented above, we find no evidence of any TfR-mediated accumulation in this 
organ. Instead, we find that the accumulation may be increased by the conjugation of 
proteins on the nanoparticle surface (e.g. antibodies). This could leave the targeted 
nanoparticles more susceptible for opsonization, and hence, uptake by macrophages 
(Kupffer cells) residing in the liver. This corresponds well with our EM-based 
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observation that AuNPs could only be detected in Kupffer cells in the sinusoids 
(Manuscript IV), whereas no AuNPs were detected inside or even binding to a 
hepatocyte. Such results have also been presented in other detailed studies of 
nanoparticle biodistribution (97, 210-212). In the spleen, the TfR expression has been 
observed throughout the tissue, although with an overweight in the red pulp and 
residing macrophages (206-208, 213). As for the liver, we performed EM on spleen 
sections to study the AuNP uptake (Manuscript IV), however, with no clear answer as 
to the type of cell, in which the AuNPs located after splenic accumulation. We 
speculate that the macrophages also in this organ are the primary cells taking up 
nanoparticles in the spleen, maybe with a TfR-mediated potential increase in 
accumulation. Experiments on anti-TfR antibodies showed that these accumulated to 
a high degree in the spleen (214), thus, also suggesting an impact of the splenic TfR 
expression on accumulation in this organ in addition to the size effect, which could be 
another explanation in the case of nanoparticles. Others have shown no additional 
spleen accumulation of TfR-targeted AuNPs after intravenous administration (210). 
However, this study was very small (n = 3) and did the assessment 24 hours after 
administration, which is not comparable to most of our time points. Still, in 
Manuscript III, we observed that the difference between isotype IgG and OX26 
immunoliposomes, with respect to splenic accumulation after 1 hour, was lost after 
24 hours, suggesting that the impact of TfR-targeting on splenic accumulation may be 
an acute phenomenon that levels out days after the administration. 
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Figure 5.3.2. Immunohistochemistry staining of TfR in healthy mouse brain, liver, and spleen. In the brain, 
the expression of TfRs are distributed evenly across the tissue, hereby staining both the brain endothelial 
cells lining the capillaries, and the surrounding neuronal cell bodies. In the liver, the expression is observed 
both on the hepatocytes and on Kupffer cells (resident macrophages, arrow). In the spleen, the expression 
is mostly observed in the red pulp, where the tissue-specific macrophages are residing. Several 
microanatomical features are illustrated in the far-right column. Scale bars depict 20 µm. 
Overcoming the issue of passive (or active) accumulation of nanoparticles in 
peripheral organs are a great interest for the field of nanomedicine. Particularly, the 
big reduction in clearance seen for PEGylated nanoparticles was a big stepping stone 
(199), although new findings indicate that the immune system will respond to the 
polymer molecules (215-221). Others have presented evidence that the molecule 
CD47 is crucial for omitting phagocytosis of nanoparticles (222, 223). For example, 
ON THE USE OF THE TRANSFERRIN RECEPTOR AS A TARGET FOR BRAIN DRUG DELIVERY 
56 
by coating targeted nanoparticles (against ICAM-1, PECAM-1, and TfR) with CD47, 
the subsequent clearance was significantly reduced, although with an increase in lung 
targeting (222). This corresponded well with a recent finding in the field of 
extracellular vesicles (here: exosomes), where CD47 was found to be the reason why 
liposomes were cleared much faster than exosomes, and how CD47 expression on the 
exosome surface ensured that the exosome was not phagocytosed by macrophages 
(223). 
In Manuscript V, we observed a severe adverse reaction after injecting the RI7 
antibody-functionalized liposomes into the systemic circulation of mice. The reaction 
happened immediately after the dose had been given, and continued for approximately 
two hours before the mice showed complete recovery. There were no observable 
reactions in the mice treated with only mPEG oxaliplatin-loaded liposomes, which 
indicates that the cause of the adverse reaction converges to the RI7 antibodies. This 
is further underscored by the fact that there seemed to be a dose-dependency of the 
adverse effects with increasing numbers of deaths per group with increasing RI7 
antibody density. The mice treated with RI7 antibody-functionalized AuNPs did not 
present with any adverse effects, which may be due to the overall low protein 
concentration in these formulations, and the possible inaccessibility of the conjugated 
RI7 antibodies for interacting with immune cells, as has been observed by others 
(224). 
We interpreted the symptoms observed in the mice as a clear indication of hemolysis 
due to TfR-targeting on circulating reticulocytes, which constitutes the majority of 
TfRs residing in the systemic circulation (225, 226). This amounts to approximately 
100,000 receptor molecules/cell with some interspecies differences (227, 228), which 
is comparable to the expression level in BCECs (229, 230). The expression will, 
however, be lost in the process yielding mature red blood cells (225). Nevertheless, 
the fact that such severe reactions can be induced by TfR-targeting should raise some 
concern when designing TfR-targeted drug constructs or nanomedicines for any 
disease indication (225, 231-233). With regards to the use of full anti-TfR antibodies 
as drugs for brain diseases, it was shown that by reducing the effector function of the 
Fc domain, the level of adverse effects (i.e. hemolysis) decreased substantially (225, 
233), whereas complete removal of the Fc domain reduced peripheral toxicity of anti-
DLL4 antibodies (234). Correlating with these observations, for many purposes of 
nanomedicine development, the use of full antibodies is often omitted in favor of 
single chain variable fragment or Fab fragments to reduce the potential of a severe 
peripheral toxicity profile (235, 236). No additional investigations into the possible 
adverse effects imposed on the BCECs were attempted, but studies on TfR antibodies 
show receptor degradation as a result of high-affinity targeting of the TfR with no 
signs of detrimental effects of the BBB integrity (193, 237-239).  
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5.4. RELEVANCE OF TRANSFERRIN RECEPTOR-TARGETING 
The popularity of TfR as a target for drug delivery has not declined since the concept 
was originally proposed in the mid-1980s (240). In Manuscript I and Manuscript II, 
detailed literature reviews were presented regarding the use of TfR as a target for 
liposome-based brain drug delivery, or for brain drug delivery in general regardless 
of the choice of drug design. In this joint discussion, only a few major points will be 
summarized (141, 163). 
Despite the discrepancy between the widely-accepted model for TfR sorting inside 
the BCECs, there is little doubt that the TfR has proven its relevance as a good target 
for getting drugs near the brain parenchyma (141, 151, 158, 163, 241, 242). This is 
evidenced in numerous reports, where the strategy has been tested in many diseases 
using many carriers. Common to many of these reports is the lack of investigation into 
the drug/nanoparticle transport itself in favor of more clinically relevant experimental 
outcomes such as improvements in preclinical models of neurodegenerative or 
neuromalignant diseases (141, 242). Some reports provide indirect evidence of 
transport, e.g. where PET tracers binding to targets inside the brain parenchyma 
indicate that successful transport did indeed happen (60, 243-245). The choice of 
leaving out any assessment of the transport qualities of the construct is not wrong, but 
it adds to the number of missed opportunities to gain knowledge about the transport 
process that we greatly need (242). The reason for this complaint is that despite loads 
of preclinical progress, we have yet to see this potential translated into clinically 
relevant ‘leads’ that can progress through the drug development process and become 
effective therapeutics for the patients (141, 242). Hence, the large number of positive 
papers regarding this targeting concept cannot hide the underlying disappointment of 
so few examples of clinical progression (e.g. TransMID (Tf-DT-CRM107) from 
Celtic Pharma, which was discontinued in early Phase III due to lack of improved 
therapeutic efficacy compared to standard care that could defend the very difficult 
handling and administration of the construct (246-249)). The picture is even worse for 
TfR-targeted nanomedicines, which illustrates how new innovations are crucial for 
the strategy to survive and prove its potential further than the preclinical stages (141, 
163). 
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Figure 5.4.1. Overview of the literature regarding transport of anti-TfR antibodies into the brain as a 
function of affinity, valency, and pH-sensitivity. The transport of different binding strategies is illustrated 
with high-affinity (bivalent) antibodies (green variable domains) are characterized by low transport (red) 
into the brain parenchyma. Conversely, low-affinity (pink variable domains), monovalency (high-affinity, 
green variable fragments), and pH-sensitivity (purple variable fragments) improve the transport into the 
brain markedly (green), hereby yielding therapeutic effects of other antibody fragments targeting 
intraparenchymal targets such as b-amyloid (yellow variable fragments). The setup of the figure was 
inspired by Freskgård et al. (2017)(151). TfR: Transferrin receptor. 
Fortunately, the recent years has seen some new design innovations to the targeting 
strategy (i.e. to the antibodies) that has proven much better than the previous designs 
both in rodent and non-human primates (Figure 5.4.1)(42, 193, 225, 238, 239, 243, 
244, 250-253). This development has been driven largely by the biotechnological and 
pharmaceutical industries that had the required resources to study concepts in depth 
that had been proposed or indicated in studies 15 – 20 years ago (65, 193, 239, 254). 
What has come out of these efforts are indeed some fascinating results showing that 
it is not enough to choose the right target, one must also have detailed knowledge 
about the interaction (i.e. binding modus) between the ligand and the TfR, since this 
seems to depict the intracellular sorting route and subsequent potential for transport 
through the BCECs (151, 241, 255). Whether it is the modulation of the overall 
antibody affinity towards the TfR (or other targets like CD98hc)(193, 225, 238, 250-
252), monovalent binding to the TfR (42, 193, 225, 238, 239, 243, 244, 250, 251), or 
even the pH-sensitivity of the binding (42, 253) will presumably be proven within the 
coming years, where it must be expected that these concepts will be tested in clinical 
trials. 
In relation to nanomedicines, very little of the abovementioned new innovations for 
the TfR-targeting ligands has been tested on nanoparticles for brain drug delivery. The 
concept of affinity was tested to some degree in one study, but here, antibodies known 
to have a very high affinity served as the low-affinity variant on liposomes (256). The 
aspects of avidity and valency was also tested in a few studies (107, 257, 258), but 
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several questions still need to be answered. The next section is devoted to a discussion 
of the findings presented in this dissertation, and how these findings may improve our 
knowledge on relevant TfR-targeting ligands for brain drug delivery. 
5.5. AFFINITY, AVIDITY, OR VALENCY – WHICH ONE IS THE 
HOLY GRAIL FOR BRAIN TARGETED NANOMEDICINES? 
An underlying question in most of the projects described in this dissertation was 
whether the recently presented evidence on antibody binding modus and subsequent 
transport into the brain could be applied in a nanomedicine setting (193, 239, 252). 
We therefore took different approaches to study the affinity, avidity, and valency 
phenomena in relation to transport of nanoparticles into the brain. An overview of the 
findings is presented in Figure 5.5.1. 
 
Figure 5.5.1. Overview of the findings related to nanoparticle transport into the brain as a function of 
affinity, avidity, and valency. The different strategies are illustrated as antibodies attached to AuNPs 
together with color coding representing their respective efficiencies in the studies presented in this 
dissertation. The use of high-affinity antibodies had a general low uptake (red) into the brain parenchyma, 
irrespective of the overall avidity of the antibodies on both AuNPs and liposomes. Low-affinity antibodies 
were found to produce modest increases (yellow) in the brain uptake of AuNPs, although the absolute 
amounts transported was still below 0.1 %ID/g. A monovalent binding antibody proved to be the best ligand 
for obtaining higher AuNP transport (green) into the brain parenchyma. The setup of the figure was inspired 
by Freskgård et al. (2017)(151). TfR: Transferrin receptor. 
In Manuscript III (49), we sought to recapitulate previous findings of liposome-based 
transport into the brain, which is an area of great dispute (163). It was evident that 
targeting the TfR on the surface of BCECs was efficient for obtaining high 
accumulation of liposomes at the BBB, but transport of the liposomes into the brain 
parenchyma could not be evidenced by our data, even though we utilized the same 
fluorescence microscopy-based approach as presented in Reimold et al. (2008)(259). 
While fluorescent signals indicative of liposomes could be readily observed, these 
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signals could largely be explained by paraformaldehyde fixation artefacts, and as 
such, it was not possible to prove transcytosis of the TfR-targeted liposomes. These 
observations were in line with what was previously shown by our group using both 
OX26 immunoliposomes or the OX26 antibody itself. OX26 is a high-affinity 
antibody directed against the rat TfR, and according to the new knowledge on 
antibody transport, it should not be able to mediate transport across the BBB. This is 
mainly due to the bivalent binding of many TfRs on the BCEC surface, which will 
induce a multimerization of the receptors, not favoring subsequent intracellular 
sorting leading to trans-BBB transport (151). Still, the antibody density used in this 
study ranged between 0.7 and 1.0 * 103 antibodies/µm2, which was shown to be 
favorable for nanoparticle delivery to the brain compared to higher densities (107, 
257).  
Instead, the cargo encapsulated in the OX26 immunoliposomes was found in the brain 
parenchyma. This finding suggests that even though the nanoparticle may not 
transport through the BBB, the cargo may be released to do so. The findings in 
Manuscript III on cargo transport showed a relatively high absolute concentration of 
cargo in the brain parenchyma, compared to what was shown for other types of cargo 
in TfR-targeted liposomes (49, 163). The concentration was also much higher than 
that measured in the brains of mice receiving RI7-functionalized, oxaliplatin-loaded 
immunoliposomes in Manuscript V. The discrepancy between these findings may be 
multifaceted. First, the experiments in Manuscript III were performed with n = 5 (49), 
whereas those in Manuscript V were performed with n = 8, thus allowing for more of 
the experimental variation to become visible. As a result, it is possible that the 
approximations of brain parenchymal transport of oxaliplatin after capillary depletion 
in Manuscript V are more valid. Second, the antibody reaction observed in animals 
receiving the RI7-functionalized immunoliposomes in Manuscript V, may have 
resulted in an increased clearance of the liposomes, which could result in an 
underestimation of the transport of oxaliplatin into the brain. Third, the species 
difference, and the difference in antibody may also have impacted the results of the 
two studies. If the difference in antibodies should have impacted the results, it 
suggests that the antibody is playing a role in the transport of the cargo into the brain 
parenchyma. However, it was especially evident in the data of Manuscript III (and 
Manuscript IV for AuNPs) that the pattern of transport into the brain seemed to scale 
with that of the initial uptake of the carrier into the BCECs (49). Therefore, we cannot 
rule out the interpretation that while the BCEC uptake may be correlated to the 
targeting qualities of the nanoparticle, the subsequent transport into the brain 
parenchyma may be the result of a passive process following the intracellular 
processing and sorting of the endocytosed nanoparticles. 
In Manuscript IV, we had the opportunity to study the aspect of both affinity and 
valency on the transport of TfR-targeted nanoparticles into the brain. For this purpose, 
AuNPs was chosen as the model nanoparticle, because it allowed for several parallel 
analyses that would not have been possible when using liposomes. Most significant 
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was the adoption of TEM and EDS as techniques for validating the transport of AuNPs 
into the brain both by visualizing the individual AuNPs and prove their content of 
gold. The results of the study suggested that there may be some impact of reducing 
the affinity of the antibody attached to the AuNP surface, but that the most prominent 
increase in AuNP transport into the brain parenchyma was observed when using an 
antibody binding to the TfR monovalently. This is an important finding, because it 
underscores the theory put forward by others that multivalent binding does not favor 
transport into the brain of antibodies or nanomedicines (151). Hence, for an antibody 
with a monovalent binding modus (bi-specific antibody or brain shuttle construct), the 
transport into the brain parenchyma is increased, and it seems (based on our data) that 
in situations of low antibody density, it holds true for nanomedicines as well. These 
findings are, however, based on work on the TfR only, and other reports suggest 
bivalent targeting modes to be beneficial for other BBB targets (260).  
In the seminal papers by the group of Mark E. Davis, it was shown that while an 
optimized density of endogenous Tf on AuNPs (analogous to a monovalent binding 
antibody) led to significantly increased brain transport, these findings could not be 
recapitulated using the same density of anti-TfR antibodies (clone RI7). The results 
of Manuscript IV support this notion, although here in a setting where the IgG protein 
structure is present in all the ligands compared. While whole nanoparticle transport 
could not be evidenced in Manuscript III (49), the experimental setup in Manuscript 
IV allowed for studying this aspect, since the AuNPs were not expected to be 
degraded. Importantly, it was possible measure increased concentrations of gold in 
the parenchymal fraction of mouse brains subjected to brain capillary depletion, and 
the AuNPs could be visualized using TEM to be present in the brain parenchyma (e.g. 
in neural processes). This underscores the findings of several papers showing that 
transport of the AuNPs across the BBB is possible, albeit often at very low levels, and 
with a clear impact of the AuNP hydrodynamic diameter on the absolute efficacy of 
transport (107, 258, 261-268). This does, however, oppose older findings showing 
that the endothelial basement membrane of the BBB will function as another barrier 
beyond the first barrier, hereby inhibiting the movement of nanoparticles into the brain 
parenchyma (269). In addition to the impact of the basement membrane, the AuNPs 
could also be bound to the TfR when exposed to the abluminal side of the BBB, which 
would inhibit its entrance into the brain parenchyma (267, 268). Nevertheless, we and 
others observe AuNPs to be present in to brain parenchyma (albeit in low numbers), 
which illustrates that some nanoparticle transport across both the BCECs and the 
underlying basement membrane is possible (107, 258, 263). Further studies should 
elucidate this transport process further, e.g. by injecting cationic AuNPs into mice and 
evaluate whether these AuNPs are sequestered in the basement membrane and 
inhibited from entering the brain parenchyma. 
As described above, the brain uptake data in Manuscript IV seems to fall into the same 
pattern as the initial uptake (i.e. gold concentration) into the BCECs, and the 
interpretation of this could be that the release of the AuNPs from the BCECs is an 
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unspecific process that it not impacted by the attached ligand. Acknowledging this 
possibility, an alternative interpretation is that what is observed is largely mediated 
by the monovalent binding modus of the anti-TfRA/BACE1 antibody. Resolving this 
is difficult, because some of the results in Manuscript IV does not follow the theory 
of high-affinity ligands. It is striking that we were unable to prove a higher level of 
capillary uptake of the anti-TfRA AuNPs (at least compared to anti-TfRD AuNPs), 
since such an observation would support the notion of high-affinity antibody (and 
nanoparticle) confinement to the brain capillaries. However, basing the expected 
outcome on findings made for single antibodies may not be fully reasonable because 
of possible nanoparticle-related uptake and sorting processes. For example, one could 
speculate that a part of the sorting between nanoparticles that are able or unable to 
transport in the BCEC happened already at the level of BCEC uptake, where the TfR 
multimerization and distorted intracellular signaling induced by high-affinity and 
multivalent binding would halt the endocytosis process. This seems not to be the case 
for single antibodies, where uptake was evidenced in many studies (correlating with 
TfR degradation)(65, 66, 69, 238, 239, 270), but whether it impacts the uptake of 
nanoparticle should be studied further. An interesting observation can be made by 
comparing the data obtained in Manuscript IV and Manuscript V. In Manuscript V, 
the group functionalized with the highest density (0.6 * 103 antibodies/µm2) had an 
uptake of 0.15 and 0.05 %ID/g in the brain capillaries and parenchyma, respectively, 
whereas in Manuscript IV, these numbers were 0.2 and 0.04 %ID/g for the anti-TfRA 
AuNP group. Both antibodies presented with a high-affinity against the mouse TfR 
when analyzed using surface plasmon resonance (anti-TfRA: KD = 21 nM, RI7: KD = 
6 nM), which is meaningful taking their equal behavior in vivo into account. Thus, 
the level of uptake of anti-TfRA AuNPs may be what can be expected from these high-
affinity antibodies on AuNPs. This was not quantified directly in other studies using 
RI7 antibodies for AuNP functionalization, making direct comparisons impossible 
(258). Based on our observations, we suggest that monovalently binding TfR-ligands 
are relevant to pursue in future studies of brain drug delivery via nanomedicines. 
In Manuscript V, the aspect of avidity/ligand density was studied in parallel on 
oxaliplatin-loaded immunoliposomes and AuNPs. This allowed for assessing both the 
transport of whole nanoparticles (AuNPs) and an encapsulated cargo (oxaliplatin). 
The choice of ligand density was based on a thorough literature review of published 
studies regarding either liposomes or AuNPs. This review illustrated that ligand 
density in many studies centered around 103 antibodies/µm2 with indications that this 
ligand density was more appropriate for trans-BBB transport of nanoparticles 
compared to higher densities. This study was therefore dedicated to analyzing 
densities lower than 103 antibodies/µm2 to see if the transport could be increased even 
further, or whether there existed a lower limit for binding, and hence, transport into 
the brain. The choice of antibody for the study was clone RI7 (full clone code: 
RI7217)(271, 272), which had been studied in our laboratory before, and shown to 
bind the mouse TfR with high-affinity. This antibody (like several other high-affinity 
anti-TfR antibodies (65)) was shown to be confined inside the BCECs after 
CHAPTER 5. JOINT DISCUSSION 
63 
endocytosis (66, 270), and thus, we did not expect it to mediate high levels of transport 
into the brain parenchyma.  
The findings of the study indicated that a lower limit of antibody density does exist, 
where no additional transport capacity is obtained compared to mPEG versions of the 
nanoparticles (AuNPs or liposomes). This was most evident for the AuNPs, whereas 
more variation was observed in the data relating to uptake of the oxaliplatin-loaded 
liposomes. Importantly, in vivo (and partly in vitro), the highest density of antibodies 
mediated the highest level of transport across the BBB (albeit in disappearingly small 
concentrations for both AuNPs and oxaliplatin-loaded liposomes), thus serving as 
validation for this observation. The inefficient transport of AuNPs and oxaliplatin 
supports the findings of several other reports using both the free RI7 antibodies or 
conjugated to AuNPs (66, 258, 270). 
Surprisingly, the two model nanoparticles studied in Manuscript V (AuNPs vs. 
oxaliplatin encapsulated in liposomes) behaved very similarly with respect to the 
fraction of the dose that reached the brain side of the BBB. This was also true when 
comparing the in vitro and in vivo data. The logical interpretation of this would be 
that both the AuNPs and liposomes are transported as whole nanoparticles across the 
BBB. However, due to time constraints, no TEM analysis was performed for this 
study before submission of this dissertation, and so, this interpretation will only rely 
on the validity and robustness of the brain capillary depletion method (49, 64). 
Furthermore, the AuNPs have a hydrodynamic diameter of approximately 70 nm, 
whereas the liposome diameter is twice as big, which raises the possibility that AuNPs 
fall within a size range, where full transcytosis is possible, whereas the liposomes are 
too big for this to happen. This is underscored in many studies, where an impact of 
size has been described for many types of nanoparticles (107, 273-275). An additional 
factor to this discussion is the observation that the most realistic outcome in an 
interaction between a liposome (lipid bilayer) and a BCEC surface is fusion between 
the two (74). Still, as described above, we observed a severe reaction to the antibodies 
on the liposome surface (presumably a reaction against the rat Fc domain or the TfR-
targeting itself), which may have caused an increase in the clearance of the liposomes 
from the circulation, wherefore the uptake of oxaliplatin into the brain parenchyma 
should be expected to be higher, and hence, approaching that of Manuscript III (49).  
5.6. CAN TFR-TARGETED NANOMEDICINES BE MODIFIED TO 
IMPROVE BRAIN UPTAKE FURTHER? 
Based on the results described throughout Manuscript III – V, TfR-mediated targeting 
seems to be a viable way to ensure preferential accumulation of nanoparticles at the 
BBB. This was evidence by varying degree of upconcentration of nanoparticles in 
BCECs compared to the amounts found in the brain parenchyma or whole brain 
homogenate. The transport across the BBB and into the brain parenchyma is, however, 
still very low regardless of the improvements presented in this dissertation.  
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The studies presented in this dissertation are all characterized by being acute with 
respect to the time points of analysis in the experimental setup, and therefore, we do 
not know how the nanomedicine strategies will behave as a continuously 
administrated drug. Also, we do not know if the low level of transport that we observe 
will be enough to mediate a therapeutic effect of the encapsulated cargo. Therefore, 
we can ask the following questions to be answered by future research: 
- Will a continuous dosing regimen lead to intraparenchymal accumulation of 
nanoparticles larger than observed for single dosing? 
 
- What is the impact of continuous dosing on peripheral organs? 
 
- What is a relevant drug concentration in the brain parenchyma, and can this 
be achieved via nanomedicine-based drug delivery? 
 
- Is the distribution of drugs entering the brain parenchyma uniform, or will 
specific regions be more fitted for nanomedicine-based drug delivery? 
 
- Can the pathophysiological process of brain diseases be exploited for 
stimuli-sensitive drug release or nanoparticle charge reversal? 
 
- Can dual-targeting approach be employed to transport through the BBB 
using two receptor transport systems?  
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CHAPTER 6. CONCLUSION 
In conclusion, the projects described in this dissertation have provided new insight 
into the utility of TfR-targeting for brain drug delivery. The results presented 
throughout the different projects have shown that TfR-targeting can facilitate acute 
accumulation in the brain capillaries following intravenous administration, which 
illustrates the exclusive endothelial expression of this protein in the brain capillaries. 
Transport of nanoparticles and encapsulated cargo was in general increased with TfR-
targeting, with pronounced effects of antibody binding modus on the absolute 
amounts accumulating inside the brain parenchyma. The observed increases in brain 
transport of nanoparticles or cargo may suffice a viable way of increasing drug 
exposure to diseased regions inside the brain parenchyma, although further studies 
should investigate how much accumulation that can be achieved with multiple dosing 
over time. Furthermore, the projects have provided large amounts of biodistribution 
data to locate the nanoparticles not entering the brain parenchyma. These peripheral 
tissues with high accumulation of nanoparticles may be sites of adverse effects upon 
continuous treatment using such a drug delivery strategy. Importantly, the results of 
the different biodistribution analyses clearly indicate that TfR-targeting will increase 
the nanoparticle exposure in the spleen. While this likely illustrates a high level of 
macrophage uptake, there should be a focus on this increased accumulation and 
potential adverse effects that this would facilitate. Lastly, efforts were made to provide 
knowledge about another administration route, namely intracerebroventricular 
administration. Using this administration route, nanoparticle penetration was seen in 
the brain cortex alongside the penetrating arteries, especially if the nanoparticles had 
a net negative surface charge. This suggests that deep areas of the brain can be reached 
by direct administration, although the value of this technique will have to be validated 
to show that this nanoparticle distribution will lead to efficient drug exposure inside 
the brain parenchyma. Together, these findings may serve as an inspiration for the 
design of nanoparticle-based drug delivery strategies of the future. If the TfR-
mediated transport into the brain parenchyma is deemed too small, the future 
strategies could possibly include a controlled release mechanism into the nanoparticle 
design, e.g. to mediate a surface charge-based uptake across the BBB after initial TfR-
mediated accumulation of nanoparticles in the brain capillaries. The way forward is 
thus to develop strategies to efficiently exit the BCECs towards the brain parenchyma. 
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